Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037948] Cross -over Study to Assess the T otal 
Systemic Exposure Bioequivalence of Budesonide, 
Glycopyrronium, and Formoterol Delivered by [CONTACT_758220] A
Parexel Study No.: PXL274083
Sponsor Study Code: D5985C00004
IND No./Eudra CT No: 118313
Study Type: Pharmacokinetics (PK)/Bioequivalence
Study Intervention ( Test Product ): Budesonide/glycopyrronium/formoterol (BGF) metered dose 
inhaler (MDI) formulated with hydrofluoroolefin (HFO) 
propellant
Study Intervention ( Reference Product ):BGF MDI formulated with hydrofluoroalkane (HFA) propellant
Therapeutic Indication: Chro nic Obstructive Pulmonary Disease
Pharmacological Class: Corticosteroid/long- acting muscarinic antagonist/ Long -acting
beta agonist
Development Phase: Phase I
Sponsor: [COMPANY_008] AB
151 85 Södertälje
Sweden
Manufacturer: [COMPANY_008] AB
151 85 Södertälje
Sweden
Study Cent er: Parexel Early Phase Clinical Unit Los Angeles
[ADDRESS_1037949]
Glendale, CA [ZIP_CODE]
[LOCATION_002] of America
Date of Protocol: Final 1.0, [ADDRESS_1037950] be restricted to relevant parties.
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 [ADDRESS_1037951] cross-over study to 
assess the total systemic exposure bioequi valence of budesonide, glycopy rronium, and 
formoterol delivered by [CONTACT_758221] (PI)
Study Center
This study will be conducted at a single study center.
Parexel Early Phase Clinical Unit Los Angeles
[ADDRESS_1037952]
Glendale, CA [ZIP_CODE]
[LOCATION_002] of America
Study Rationale
This study will be conducted to demons trate that budesonide/glycopyrronium/formoterol 
metered dose inhaler with hydrofluoroolefin (BGF MDI HFO) provides equivalent total 
systemic exposure for budesonide, glycopyrronium, and formote rol compared with the 
currently approved BGF MDI with hydrofluoroalkane (HFA).
A randomized, double-blind, single-dose, cross-ove r, partial-replicate study design has been 
chosen to prevent bias in allocation of treatments in each treatment period, to minimize any 
bias from the subjects, investigator, or sponsor that may affect the study results and to allow 
determination of within-subject variability and possible expansion of the bioequivalence 
criteria limits.
Number of Subjects Planned
A total of [ADDRESS_1037953] enrolled: October 2022 (signing of informed consent)Estimated date of last subject completed: April 2023
Study Objectives
The objectives of the study are:
Primary Objective:
!To assess the bioequivalence of the total systemic exposure of budesonide, 
glycopyrronium, and formoterol  administered as BGF MDI HFO compared with BGF 
MDI HFA.[COMPANY_003]
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 3of 97Secondary Objectives:
To characterize the pharmacokinetic (PK) profiles of budesonide, glycopy rroni um, and 
formoterol  administered as BGF MDI HFO and BGF MDI HFA.
To assess the safet y and tol erabilit y of single doses of BGF MDI HFO and BGF MDI 
HFA in healt hy subjects.
Exploratory Objective:
Not applicable.
Study Design
This is a Phase I, randomized, double -blind, single -dose, single- center, cross -over study  to 
assess the PK and safet y of BGF MDI in healthy subjects (male or female). Pharmacokinet ic 
profiles of each act ive ingredient (budesonide, glycopy rroni um, and form oterol ) will  be 
determined after administration of BGF MDI HFO (test) and BGF MDI HFA (reference) 
following an overnight fast of at least [ADDRESS_1037954] will receive 3 single dose 
treatm ents of BGF MDI:
Treatment A: BGF MDI HFO 160/7.2/4.8 µg ex -actuator; [ADDRESS_1037955] formulat ion; administered during 1 treatment period.
Treatment B: BGF MDI HFA 160/7.2/4.8 µg ex -actuator; 4 inhalat ions as a single dose -
reference formulation ; administered during 2 treatment periods .
Subjects will receive treatments in 1 of 3 possible treatment sequ ences: ABB, BAB, BBA. 
The reference formulat ion will be administered during [ADDRESS_1037956] variabilit y.
The study  will com prise:
A screening period up to [ADDRESS_1037957] dosing;
Three Treatm ent Peri ods: subjects will be resident at the Clinical Unit from the morning 
on the day  before dosing wi th BGF MDI on Day -1 of Treatment Period 1, un til 24 hours 
following the final dose onDay 2 of Treatment Period 3 with a washout period of 
3to7days between ea ch dose; and
Follow-up: final safet y Follow-up Phone Call wit hin [ADDRESS_1037958] will be invo lved in the study  for approximately 55 days.
Targeted Stu dy Population
This study  will be conducted in healthy male and female subjects, 18 to 60years of age .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 4of 97Study Intervention
Arm Name [CONTACT_758262]/Glycopyronium/ 
Formoterol fumarate pressurized 
inhalation suspension, HFOBudesonide/Glycopyronium/ 
Formoterol fumarate pressurized 
inhalation suspension, HFA 
Type Combination product Combination product
Dose formulation MDI MDI
Unit dose strength(s) 
(delivered dose)160/7.2/4.8 μg per actuation 160/7.2/4.8 μg per actuation
Dosage level 4 inhalations 4 inhalations
Route of administration Oral inhalation Oral inhalation
Use Experimental Comparator
IMP and NIMP IMP IMP
Sourcing Provided centrally by [CONTACT_758222]. Each MDI will be label edas 
required per country requirements.Study intervention will be provided in 
an MDI. Each MDI will be label edas 
required per country requirements.
BGF = budesonide, glycopyrronium, formoterol; HFA = hydrofluoroalkane; HFO = hydrofluoroolefin; 
IMP =investigational medicinal product; MDI = metered dose inhaler; NIMP = non -investigational medicinal 
product.
Dosing instructions and dispensing details will be provided by [CONTACT_38227].
Budesonide, glycopy rroni um, and form oterol  MDI is a combinat ion product (drug +device).
Outcome Endpoints
Safety and Tolerability Endpoints:
Safety and tol erabilit y variables will include
Adverse events (AEs) /serious adverse events (SAEs)
Vital signs (systolic and diastolic blood pressure [BP] , pulse rate, body temperature, and 
respi [INVESTIGATOR_2842])
12-lead electrocardiograms (ECGs)
Physical examinat ion
Laboratory  assessments (hematology , clinical  chemistry , and urinalysis)
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 5of 97Viral serol ogy and drugs of abuse, alcohol and cotinine will be assessed for eligibilit y. 
Follicle-stimulating horm one (FSH) (females only), pregnancy  testing (females only ) and use 
of concomitant m edicat ion will also be assessed and reported.
Pharmacokin etic Endpoints:
Where possible, PK parameters will be assessed for budesonide, glycopy rroni um, and 
formoterol .
Primary PK parameters: AUCinf, AUClast, and Cmax
Secondary  PK parameters: tmax, λz, t½λz, MRTinf, CL/F, and Vz/F
Addit ional PK parameters may  bedetermined where appropriate.
Exploratory Endpoints:
Not applicable.
Statistical Methods
Presentation and Analysis of Pharmacokinetic Data:
Plasma concentrations for each analy te (budesonide, glycopy rroni um, and form oterol ) will  be 
listed by  [CONTACT_758223], subject and time point. Plasma concentrations will also be 
summarized by  [CONTACT_758224] t imes and 
appropriate descript ive statistics.
The stati stical analysis will be performed for the PK analysis set. Pharmacokinetic parameters 
will be calculated using non- compartmental analysis.
For each analyte, individual plasma concentrations versus actual time will be plotted in linear 
and semi -logarithmic scale wi th all treatm ent occasi ons overl aid on the sa me plot and separate 
plots for each subject. Combined individual plasma concentration versus actual times will be 
plotted in linear and semi -logarithmic scale for each treatment occasion and analy te. 
Geom etric mean pl asma concentrati on (± g eometric standar d deviat ion [gSD]) versus no minal 
sampling t ime will be plotted in linear and semi -logarithmic (no standard deviat ion [SD]
presented) scale with all treatment occasions overlaid on the same figure.
Plasma PK parameters will be listed and summarized using descript ive statist ics for each 
treatm ent occasi on and analy te. Where possible, the following descript ive statist ics will be 
presented: n, geometric mean, geometric co -efficient of variat ion, ari thme tic mean, ari thmet ic 
SD, m edian, minimum, and maximum. For tmax, only  the number of subjects (n) , median, 
minimum, and maximum will be presented.
Bioequivalence will be assessed between test treatment BGF MDI HFO and reference 
treatm ent BGF MDI HFA, based on the PK analysis set.
Presentation and Analysis of Safety and Eligibility Data:
All safet y data (scheduled and unscheduled) will be presented in the data list ings. Continuous 
variables will be summarized using descript ive statist ics (n, m ean, SD, minimum, median, 
maximum) by  [CONTACT_3227]. Categori cal variables will be summarized in frequency tables 
(frequency and proportion) by [CONTACT_3148] /dose group. The analysis of the safet y variables will 
be based on the safety  analysis set.
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 6 of 97Adverse events will be summarized by [CONTACT_758225]. Furthermore, listings of SAEs and AEs that 
led to the discontinuation (DAE) of investigational medicinal product (IMP) will be made. 
Adverse events that occur before dosing will be reported separately.
Tabulations and listings of data for vital signs, clinical laboratory tests, ECGs, will be 
presented. Any new or aggravated clinically relevant abnormal medical physical examination 
finding compared to the baseline assessment will be reported as an AE. Data will be 
summarized for the observed values at each scheduled assessment, together with the 
corresponding changes (and/or percentage change) from the baseline when baseline is defined. 
Clinical laboratory data will be reported in the units provided by [CONTACT_758226], and in Système International units in the Clinical Study 
Report.
Out-of-range values for safety laboratory will be flagged in individual listings as well as 
summarized descriptively using agreed reference ranges (eg, laboratory ranges).
Determination of Sample Size:
The sample size for this study was based on  
 
 
 
 
 
 
The number of subject identifiers generated for the study will account for the number of 
randomized subjects per the sample size calculation (N = 108). For this study, a total of 
[ADDRESS_1037959] identifiers will be randomly assigned to 1 of 3 possible treatment sequences: 
ABB, BAB, BBA.CCI
CCI
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037960] ions................................................................................. 35
[IP_ADDRESS]. Women of Non -Childbearing Potential ............................................................. 35
[IP_ADDRESS]. Women of Childbearing Potential ..................................................................... 35
[IP_ADDRESS]. Male Subjects ................................................................................................... [ADDRESS_1037961] Enrollment and Rando mizat ion............................................................ 37
5.1.1. Procedures for Rando mizat ion.......................................................................... 37
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037962] -study  Treatm ent(s) ......................................................... [ADDRESS_1037963]-treatm ent Follow -up Peri od.................................................... 45
6. COLLECTION OF STUDY VARIABLES ....................................................... 46
6.1. Recording of Data ............................................................................................. 46
6.2. Enrollment and Screening Procedures ............................................................... 46
6.3. Safety and Eligibilit y Measurements ................................................................. 46
6.3.1. Adverse Events ................................................................................................. 46
[IP_ADDRESS]. Definit ion of Adverse Events ............................................................................ 46
[IP_ADDRESS]. Definit ions of Seri ous Adverse Event ............................................................... 46
[IP_ADDRESS]. Other Si gnificant Adverse Events ..................................................................... 47
[IP_ADDRESS]. Recording of Adverse Events ............................................................................ 47
[IP_ADDRESS]. Reporting of Serious Adverse Events ................................................................ 50
[IP_ADDRESS]. Regulatory  Reporting Requirements for Serious Adverse Events ...................... 51
[IP_ADDRESS]. Medical Device -related Safet y Events ............................................................... 51
[IP_ADDRESS]. Medical Device Deficiencies ............................................................................. 52
6.3.2. Laboratory  Assessments ................................................................................... 53
[IP_ADDRESS]. Hem atology...................................................................................................... 53
[IP_ADDRESS]. Serum  Clinical Chemistry ................................................................................. 53
[IP_ADDRESS]. Urinalysis ......................................................................................................... 54
[IP_ADDRESS]. Pregnancy Testing ............................................................................................ 54
[IP_ADDRESS]. Viral Serol ogy.................................................................................................. 54
[IP_ADDRESS]. Drugs of Abuse, Alcoho l and Cotinine .............................................................. 54
[IP_ADDRESS]. COVID -19 Testi ng........................................................................................... 54
6.3.3. Physical Examinat ion........................................................................................ 55
6.3.4. Electrocardiograms ........................................................................................... 55
[IP_ADDRESS]. Safety 12-lead ECGs ......................................................................................... 55
6.3.5. Vital Signs........................................................................................................ 55
6.3.6. Spi[INVESTIGATOR_038]........................................................................................................ 56
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037964] ion of Pharmacokinet ic Samples ............................................................ 56
[IP_ADDRESS]. Plasma Samples ................................................................................................ [ADDRESS_1037965] Samples .................................................. 58
7.4. Chain o f Custody  of Biological  Samples ........................................................... 58
7.5. Withdrawal o f Informed Consent for Donated Bio logical Sam ples.................... 59
8. REGULATORY AND ETHIC AL CONSIDERATIONS .................................. 60
8.1. Regulatory  and Ethi cal Considerat ions.............................................................. 60
8.2. Data Protection ................................................................................................. 60
8.3. Inform ed Consent Process ................................................................................. 61
8.4. Insurance .......................................................................................................... 61
9. DAT A QUALITY ASSURAN CE AND DATA MANAGEME NT................... 62
9.1. Qualit y Control  and Source Data Verificat ion................................................... 62
9.2. Audit/Inspect ions.............................................................................................. [ADDRESS_1037966] ion................................................................................................. 62
9.4.1. Case Report Forms and Source Documents ....................................................... 63
9.4.2. Access to Source Documents ............................................................................ 63
9.5. Data Management ............................................................................................. 63
10. EVALUATION AND CALCU LATION OF VARIABLES .............................. 65
10.1. Safety Variables ................................................................................................ 65
10.1.1 . Adverse Events ................................................................................................. 65
10.1.2. Laboratory  Assessments ................................................................................... 66
10.1.3. Physical Examinat ion........................................................................................ 66
10.1.4. Resting 12 -lead Electrocardiogram ................................................................... 67
10.1.5. Vital Signs........................................................................................................ 67
10.2. Pharmacokinet ic Variables ................................................................................ 67
10.2.1. Plasma Parameters ............................................................................................ 67
10.2.2. Calculation or Derivat ion of Pharmacokinet ic Parameters ................................. 68
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 10of 9710.3. Pharmacodynamic Variable(s) .......................................................................... [ADDRESS_1037967] ics...................................................................................... 72
[IP_ADDRESS]. Dem ographic and Baseline Data ....................................................................... 72
11.2.4. Prior and Concomi tant Medicat ion and Drug Administration ............................ 73
[IP_ADDRESS]. Prior and Concomi tant Medicat ion.................................................................... 73
[IP_ADDRESS]. Study  Intervent ion Administration .................................................................... [ADDRESS_1037968] ives and Outcome Measures ......................................... 21
Table 3-1 Schedule of Assessments ......................................................................... 24
Table 3-2 Expected Duration of the Study ............................................................... 27
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037969] of Appendices
Appendix A Addit ional Safet y Informati on.................................................................. 84
Appendix B International Airline Transportation Associat ion 6.2 Guidance Document 86
Appendix C Actions Required in Cases of Co mbined Increase of Aminotransferase 
and Total Bilirubin -Hy’s Law ................................................................ 87
Appendix D Medical Device AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and Medical 
Device Deficiencies: Definit ions and Procedures for Recording, 
Evaluat ing, Follow -up, and Reporting in Medical Device Studies ............ 92
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037970] OF ABBREVIATION S AND DEFINITION OF TERMS
Please note definit ions of abbreviat ions for pharm acokinet ic variables are presented in
Secti on10.2.1 of this protocol .
Abbreviation or 
special termExplanation
ABE average bioequivalence
AE Adverse event (see definition in Section 6.3.1 )
AIM Aerosol inhalation monitor
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AMP Amphetamine
AST Aspartate aminotransferase
ATS/ERS American Thoracic Society/European Respi[INVESTIGATOR_758211], glycopyrronium, formoterol
BMI Body mass index
BP Blood pressure
bpm Beats per minute
BUP Bupreno rphine
BZO Benzodiazepi[INVESTIGATOR_758212]™ Parexel's electronic source data capturing and information management system
CO [ADDRESS_1037971] research organization
CRP C-reactive protein
CSP Clinical study protocol 
CSR Clinical study report 
CV Co-efficient of variation
CV% Percentage co -efficient of variation
DAE Adverse event leading to discontinuation (of IMP)
DCF Data clarification form
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037972] second
FSH Follicle -stimulating hormone
FVC Forced vital capacity
GCP Good Clinical Practice
GGT Gamma glutamyl transpeptidase (transferase)
GMP Good Manufacturing Practice
GMR Geometric mean ratio
gSD Geometric standard deviation
GWP Global warming potential
Hb Hemoglobin
HBsAg Hepatitis B surface antigen
HCT Hematocrit
HFA hydrofluoroalkane
HFO hydrofluoroolefin
HIV Human immunodeficiency virus
IATA International Airline Transportation Association
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
ICS Inhaled corticosteroid
IEC Independent Ethics Committee
Ig Immunoglobulin
IMP Investigational medicinal product
IRB Institutio nal Review Board
LABA Long -acting β2 agonist
LAMA Long -acting muscarine agonist
LLOQ Lower limit of quantification
MCH Mean corpuscular hemoglobin
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037973] Medical Device Regulation
MedDRA Medical Dictionary for Regulatory Activities
MET Methamphetamine
MTD Methadone Metabolites
n Number of subjects
NC Not calculated
NGP Next generation propellant
NIMP Non-investigational medicinal products
NQ Not quantified
OAE Other significant adverse events
OPI [INVESTIGATOR_758213] -the-counter
OXY Oxycodone
PCP Phency clidine
PCR Polymerase chain reaction
PI [INVESTIGATOR_244873] (s)
PR(PQ) ECG interval measured from the onset of the P wave to the onset of the QRS 
complex
QRS ECG interval measured from the onset of the QRS complex to the J point
QT ECG interval measured from the onset of the QRS complex to the end of the T 
wave
QTcB QT int erval corrected for heart rate using Bazett's formula
QTcF QT interval corrected for heart rate using Fridericia’s formula
RBC Red blood cell
RR The time between corresponding points on [ADDRESS_1037974]
SAE Serious adverse event (see definition in Section [IP_ADDRESS] ).
SAP Statistical Analysis Plan
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037975] Upper limit of normal
[LOCATION_003] [LOCATION_002] of America
WAD Windows Allowance Document
WBC White blood cell
WOCBP Women of childbearing potential
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 16 of 97INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE
Sponsor: [COMPANY_008] AB
151 85 SödertäljeSweden
Sponsor’s Lead 
Physician:
Tel: 
Email: 
Sponsor’s 
Biostatistician:
Email: 
Principal 
Investigator:
[INVESTIGATOR_36113]: 
Email: 
Contract 
Research 
Organization:
Tel: 
Fax: 
Clinical 
Laboratory:
Phone: 
Fax: 
Email: 
Analytical 
Laboratory(pharmacokinetic sample analysis):All laboratories used to analyze samples taken for this study will be detailed in the 
Laboratory Manual.[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003][COMPANY_003][COMPANY_003][COMPANY_003]
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 17 of 97Adverse Event 
Reporting:[COMPANY_008] Patient Safety Data Entry Site
Tata Consultancy ServicesFax: 
Email: 
A list and contact [CONTACT_720466] F ile. A list of all participating investigators will 
be provided in the Clinical Study Report.[COMPANY_003][COMPANY_003]
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 18of 971. INTRODUCTION
1.1. Background Information
[COMPANY_008] has developed BGF MDI HFA as a maintenance treatment in adult patients with 
COPD wi th moderate to severe airflow obstruction who are not adequately  treated by  a 
combinat ion of an ICS and a LABA or a combinat ion of a LABA and a LAMA.
The drug substances in BGF MDI HFA are budesonide, glycopy rroni um bromide 
(glycopy rrolate), and form oterol fumarate dihydrate. Budesonide is a synt hetic glucocortico id 
receptor agonist with well -established ant i-inflammato ry properti es that exhibits potent 
glucocorti coid and weak mineralocortico id act ivity. Glycopy rroni um bromide is a synt hetic 
LAMA, and glycopy rroni um is the act ive moiety of this bromide salt form (9 μg of 
glycopy rroni um bromide is equivalent to 7.2 μg of glycopyrronium). Glycopyrronium exerts 
its bronchodilatory  effect via m uscarinic receptors located on smooth muscle cells wit hin the 
trachea and bronchi. Formoterol fumarate dihydrate is a synt hetic LABA used as its fumarate 
salt in dihydrate form (5 μg of formoterol  fumarate dihydrate i s equivalent to 4.8 μg of 
formoterol  fumarate). F ormoterol  fumarate i s a potent and select ive LABA that acts locally in 
the lung as a bronchodilator when inhaled. Formoterol fumarate stimulates β2 adrenoreceptors 
in the airw ays, inducing airway  smooth muscle relaxat ion and reducing or prevent ing 
bronchoconstrict ion. More informat ion on budesonide, glycopy rroni um, and form oterol  
fumarate can be found in the Invest igator’s Brochure 2022.
The BGF MDI HFA product is formulated with HFA -134a propellant, a liquified co mpressed 
gas, in which the budesonide, glycopy rroni um bromide, and formoterol fumarate dihydrate are 
suspended. HFA -134a is a co mmo n propellant in pharmaceutical MDI products that provides 
the force to generate an aerosol to deliver a product inhalat ion or dose. This drug product is an 
MDI form ulated as a suspensio n with micronized active pharmaceut ical ingredients and 
Co-Suspensio n™ Delivery Technology . The Co -Suspensio n™ Delivery  Technol ogy consists 
of spray -dried porous parti cles co mprised of the phospholipid 1,2-distearoyl sn glycero 
3-phosphocho line and calcium chloride suspended in a nHFA propellant. When used in 
combinat ion MDI products, these particles form strong non -specific associat ions wit h the 
active pharmaceut ical ingredients, prevent ing the drugs fro m interacting with each other in the 
suspension and providing reproducible drug delivery  and l ong-term stabili ty. More 
information on the BGF MDI HFA product is described in the Invest igator’s Brochure 2022.
The current HFA propellant is known to have a relatively high GWP co mpared with some 
alternat ive propellants and contributes substant ially to the sponsor, [COMPANY_008]’s carbon 
footprint. The reformulat ion of [COMPANY_008]’s MDI products with an NGP that has much 
lower GWP will allow pat ients to continue to use MDI ty pe treatm ents while contribut ing to 
[COMPANY_008]’s sustainabilit y efforts.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037976] igator’s Brochure 2022.
Addit ionally , 1clinical study  (D598 5C00001) assessing the relat ive bioavailabilit y between 
3BGF MDIs formulated with 3 different propellants, ie, HFO (test), HFC (test) and HFA 
(reference), in healt hy male adults (age 18 to 60 y ears) has been com pleted. Systemic 
exposure to budesonide, glycopy rroni um, and formoterol  was similar for BGF MDI HFO, 
BGF MDI HFC and the reference product BGF MDI HFA. Safet y and tol erabili ty data from  
the study  did not rai se any safet y concerns. There were no deaths, SAEs, or AEs that led to 
discontinuat ion of BGF MDI reported during the study . There were no notable differences 
between the treatments given regarding number of vo lunteers reporting AEs, number of 
events, assessed relationship, or severit y. No clinically  relevant trends were observed for vital 
signs, physical examinat ion, laboratory  resul ts, spi[INVESTIGATOR_247190], and taste assessment, and no 
abnorm al clinically significant 12 -lead safet y and di gital ECG, as well as cardi ac tel emetry  
findings were reported. The combinat ion of BGF when administered as single do ses in 
3different propellant formulat ions dem onstrated an acceptable safet y profile and was well 
tolerated in the studi ed popul ation.
The aim of the current study  is to assess the bioequivalence of the total systemic exposure of 
budesonide, glycopy rroni um, and f ormoterol administered as BGF MDI HFO co mpared with 
BGF MDI HFA.
1.2. Rationale for Conducting this Study
The current propellant in BGF MDI HFA (HFA -134a) is known to have a relatively high 
GWP co mpared to CO 2and contributes substant ially to [COMPANY_008] ’s carbon footprint. In 
order to address this issue [COMPANY_008] is evaluat ing a potential alternative propellant (HFO) 
with a much l ower GWP which will allo w pati ents to continue to use MDI ty pe treatm ents 
while contributing to [COMPANY_008]’s sustainabilit yefforts. The reformulat ion of [COMPANY_008]’s 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 20of 97MDI products with the new propellant that has much lower GWP will allow patients to 
continue to use MDI ty pe treatm ents while contributing to [COMPANY_008]’s sustainabilit y 
efforts. As part of the clinical develop ment program for gaining regulatory  approval  of BGF 
MDI HFO, this study  is being conducted to demonstrate that it provides equivalent total 
systemic exposure for budesonide, glycopy rroni um, and f ormoterol com pared wi th the 
currently approved BGF MDI HFA.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037977] and reference 
treatment
BGF = budesonide, glycopyrronium, formoterol; HFA = hydrofluoroalkane; HFO = hydrofluoroolefin; 
MDI =metered dose inhaler ; PK = pharmacokinetic(s) .
2.2. Secondary Objectives
Table 2-2 Secondary Objectiv es and Outcome Measures
Secondary Objectives Outcome Measures
To characterize the PK profiles of budesonide, 
glycopyrronium, and formoterol administered as BGF 
MDI HFO and BGF MDI HFAtmax, λz, t½λz, MRTinf, CL/F ,and Vz/F
To assess the safety and tolerability of single doses of 
BGF MDI HFO and BGF MDI HFA in healthy 
subjects• AEs and SAEs.
• Vital signs (systolic and diastolic BP,pulse rate, 
body temperature, and respi[INVESTIGATOR_697] ).
• 12 -lead ECG.
• Physical examination.
• Laborato ry assessments (hematology, clinical 
chemistry , and urinalysis).
AE = adverse event; BGF = budesonide, glycopyrronium, formoterol; BP = blood pressure; 
ECG =electrocardiogram; HFA =hydrofluoroalkane; HFO = hydrofluoroolefin; MDI =metered dose inhaler; 
MRT =mean residence time; PK = pharmacokinetic(s) ; SAE = serious adverse event .
Refer to Section 10.2 for PK variables, Section 6.3for safet y variables.
2.3. Exploratory Objective s
Not applicable.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 22of 973. STUDY DESIGN
3.1. Overall Study Design and Flow Chart
This is a Phase I, randomized, double -blind, single -dose, single -center, cross -over study  to 
assess the PK and safet y of BGF MDI in healthy subjects (male or female). Pharmacokinet ic 
profiles of each act ive ingredient (budesonide, glycopy rroni um, and form oterol ) will  be 
determined after administration of BGF MDI HFO (test) and BGF MDI HFA (reference). The 
study  will com prise:
A screening period up to [ADDRESS_1037978] dosing;
Three Treatm ent Periods: subjects will be resident at the Clinical Unit from the morning 
on the day  before dosing wi th BGF MDI on Day -1of Treatm ent Peri od 1, until 24 hours 
following the final dose on Day 2 of Treatm ent Period 3 ,with a washout period of 
3to7days between each dose; and
Follow-up: final safet y Follow-up Phone Call within 3to7 day s after the last 
administration of BGF MDI in Treatment Period 3.
Each subject will receive 3single dose treatments of BGF MDI following an overnight fast of 
at least 8 hours :
Treatment A: BGF MDI HFO 160/7.2/4.8 µg ex -actuator; [ADDRESS_1037979] formulat ion; administered during 1 treatment period.
Treatment B: BGF MDI HFA 160/7.2/4.8 µg ex -actuator; 4 inhalat ions as a single dose -
reference formulation ; administered during 2 treatment periods .
Subjects will receive treatments in 1 of 3 possible treatment sequences: ABB, BAB, BBA .
The reference formulat ion will be administered during [ADDRESS_1037980]’s 
assigned rando mization (see Sect ion 5.1) is presented in  Figure 3-1. The SoA displaying 
assessments/tasks and time po ints is presented in Table 3-1.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037981] dose
V = visit .
This is a partial -replicate 3 -period cross -over study. Subjects will be randomly assigned to 1 of 3 treatment 
sequences: ABB, BAB, BBA, where Treatment A: BGF MDI HFO (test), Treatment B: BGF MDI HFA 
(reference).

Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 24of 97Table 3-1 Schedule of Assessments
ScreeningTreatment Periods 1, 2, and 3 aEarly Termination Visit (within 
3to 7days post final dose)Follow -up Phone Call (within 
3to 7days post final dose) Day -1 Day 1 to 2
Informed Consent X
Assignment of enrol lment
numberX
Inclusion/exclusion criteria X X b
Demographic data X
Medical history X
Urinary  drug/cotinine and 
serum alcohol screenX X b
Concomitant medication X X X X
Serology X
COVID -19 X Xb
FSH (post menopausal
women only)X
Pregnancy testing (females 
only)X
(serum)X
(serum/urine)X c
(urine)X
(urine)
Randomization X
(Day  1 of Treatment 
Period 1)
Study residency
Check -in X
(morning)
Check -out X
Day 2 ([ADDRESS_1037982]-dose in 
Treatment Period 3)
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 25of 97ScreeningTreatment Periods 1, 2, and 3 a
Early Termination Visit (within 
3to 7days post final dose)Follow -up Phone Call (within 
3to 7days post final dose) Day -1 Day 1 to 2
Inhalation Practice
Device and inhalation 
training with placebo and 
with AIM trainerX X X
(prior to dosing)
IMP administration Day 1 (0hours of 
each treatment 
period )
Safety and tolerability
Adverse events X dX X X X
Vital signs (BP, pulse rate, 
body temperature, and 
respi[INVESTIGATOR_2842])X X XeX
12-lead ECG X XcX
Spi[INVESTIGATOR_038] X
Clinical laboratory 
evaluationsX XcX
Urinaly sis X XcX
Physical examination X X fXcX
Body weight X XcX
Pharmacokinetics
Plasma for budesonide, 
glycopyrronium, and 
formoterolX
(pre-dose and 2, 5, 
10, 20, 30, and 
45minutes post -dose 
and 1, 2, 4, 8, [ADDRESS_1037983] -dose)
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 26of 97AIM = aerosol inhalation monitor; BP = blood pressure; COVID = corona virus disease; ECG = electrocardiogram; FSH = follicle -stimulating hormone; 
IMP =investigational medicinal product ; SAE = serious adverse event.
aThere will be a [ADDRESS_1037984] -dose.
fA brief physical examination will be performed.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037985] for the proposed timing is that phy siological assessments such as 
heart rate or BPas well as inquiring for AEs should not be accidentally influenced by [CONTACT_758227] a venous puncture. The sequence at a particular time point i s:
1Electrocardiograms
2Vital signs ( BPand pulse rate, body  temperature, and respi[INVESTIGATOR_2842])
3Safety and PKblood sam pling (order of standard blood sampling to be fo llowed)
Pre-dose assessments (except for pre -dose PK assessments) may be performed up to 
60minutes prior to dosing. In the event of a delay due to technical or logist ical issues wi th the 
vital signs assessment, PK blood sampling should be priorit ized.
Details o f acceptabl e tolerance windows for safet y and PK assessments will be included in a 
WAD which will be agreed upon and signed off before the start of the study.
3.1.2. End of Study
The end o f study  is defined as the last subject’s Follow -up Phone Call from the Clinical Unit.
3.1.3. Expected Duration of the Study
Each subject will be invo lved in the study  for approximately [ADDRESS_1037986] dosing.
Treatment Periods 1, 2, and 3Three Treatment Periods: Subjects will be resident at the Clinical Unit from 
the mo rning on the day before dosing with BGF MDI on Day -1of 
Treatment Period [ADDRESS_1037987] administration of BGF MDI.
Total Duration Up to 55 days .
BGF = budesonide, glycopyrronium, formoterol; MDI = metered dose inhaler.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037988] of bioequivalence studies.
3.2.2. Dose Rationale
The dose to be administered (ie, 4 inhalat ionsas a single dose ) is higher than the approved 
therapeuti c dose (2 inhalat ions) in order to increase drug exposure and calculate reliable PK 
param eters.
This study  will employ a parti al-replicate desi gn in whic h the reference treatment is 
administered on [ADDRESS_1037989] variabilit y and potentially widen 
the 90% CI limits (see Sect ion 11).
3.3. Risk- benefit Assessment
A detailed description o f the chemistry , pharmaco logy, efficacy , safety, known and expected 
benefits, and potential risks of BGF MDI is provided in the Invest igator’s Brochure 2022. 
Overall, BGF MDI is well tolerated, especially  consi dering that thi s study  includes only  
single- dose administrati ons.
Since the test product is a reformulat ion based on a change in the excipi[INVESTIGATOR_718091]:
The active ingredients are the same.
Treatment is expected to be as safe as it was previously.
Inhaler device of reformulated drug is same as previous inhaler.
NGPs are not expected to be environmentally  damaging.
One clinical trial with the NGP -based products has been completed with acceptable safet y 
resul ts.
Hydrofluoroolefin (HFO)
Hydrofluorool efin was negative in a battery  of genotoxi city tests. It was also very  well  
tolerated in single -dose (m ouse and rat) and repeat- dose (rat and dog) toxico logy studi es. 
Refer to the I nvest igator’s Brochure 2022for more details on nonclinical studies wit h HFO.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 29of 97Addit ionally , safet y and tol erabili ty data f rom the clinical study  assessing the relative 
bioavailabilit y between 3 BGF MDIs formulated with 3 differen t propellants (see Section 1.1), 
did not raise any  safety  concerns. The combinat ion of BGF when administered as single doses 
in [ADDRESS_1037990] of the study .
Measures to mitigate the addit ional risks caused by [CONTACT_4113] -19 are:
This study  is going to start enrolling only when the sponsor and CRO in co llaboration 
deem  it is safe to start the study . In addi tion, the study  will not start until the local 
confinement measures or o ther safet y restri ctions linked to the COVID -19 pandemic is
lifted by  [CONTACT_941] l ocal authori ties.
Current national laws and local reco mmendat ions for prevent ion of pandemic will be 
strictly adhered to.
Subjects will be closely mo nitored for any  signs and sympto ms of COVID -19, including 
fever, dry  cough, dy spnea, sore throat , and fatigue throughout the study . Once clinical 
signs of  infect ion are reported by  [CONTACT_1766], the investigator needs to determine whether 
samples can be collected, and safet y data can be reco rded on site. If not, AEs and 
concomitant medicat ions will be obtained via phone calls. Daily body  temperature 
measurements during in -house stay  and outpati ent visit s will be implemented.
The invest igator will not dose subjects upon identificat ion of any  signs of COVID -[ADDRESS_1037991] ion.
Confirmation o f COVID -[ADDRESS_1037992] ion by [CONTACT_271137] y (test capaci ty and turnaround time) of approved tests and 
on invest igator’s discretion. This would include serology tes ting at screening and virus 
testing prior to any  admissio n.
The probabilit y of virus transmission will be controlled as much as possible by:
Advising the subject to adhere to local requirements for reduction of the public 
exposure while ambulatory .
If applicable, all subjects will be contact[CONTACT_758228]- [ADDRESS_1037993] wi th a person 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 30of 97who has tested posit ive for SARS -CoV -2. If applicable, subjects will be referred to 
the local health care system  for further foll ow-up and treatm ent.
Physical distancing and person- to-person contact [CONTACT_758229] -house confinement.
Where physical distancing is not possible, personal protective equipment will be used 
by [CONTACT_1766] (surgi cal face m ask, gl oves) and staff (for example, but not limit ed to 
masks, gl oves, protectors, medical suits) if deemed appropriate by  [CONTACT_758230].
Logist ical improvements of the site and structural measures of the study  site building 
will be implemented to further improve physical distancing.
3.3.2. Benefits
No benefit for individuals in this study  is expected.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1037994] igator.
4.1.1. Inclusion Criteria
For inclusio n in the study  subjects should fulfil lthe following cri teria:
1Provisio n of signed and dated, written informed consent prior to any study specific 
procedures.
2Healthy male andfemale subjects aged [ADDRESS_1037995] a BMI between 18 and 3 5kg/m2inclusive and weigh at least [ADDRESS_1037996] a FEV1 ≥ 80% of the predic ted norm al value and an 
FEV1/FVC >70% regardi ng age, height, and ethnicit y at the Screening Visit.
6Subjects m ust dem onstrate proper inhalat ion technique and have the abilit y to properly  
use an MDI device after training.
4.1.2. Exclusion Criteria
Subjects will not enter the study  if any of the fo llowing exclusio n criteria are fulfilled:
1History  of any clinically significant disease or disorder which, in the opi[INVESTIGATOR_1070] , may eit her put the vo lunteer at risk because of participation in the study, or 
influence the results or the vo lunteer’s abilit y to parti cipate in the study .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 32of 972History  or presence of gastrointestinal, hepat ic,or renal disease, or any  other condi tion 
known to interfere wit h absorption, distribut ion, metabolism, or excretion of drugs.
3Any clinically  significant illness, medical/surgical procedure, or trauma within [ADDRESS_1037997] administration o f IMP.
4History  of narrow angl e glaucom a not adequately treated and/or change in visio n that may  
be relevant. All medicat ions approved for control of intraocul ar pressures are allowed, 
including topi[INVESTIGATOR_406721] -select ive βblockers and prostaglandin analogues.
5History  of symptom atic prostatic hypertrophy or bladder neck obstruction/urinary 
retenti on that, in the opi[INVESTIGATOR_3078] n of the investig ator, is clinically significant .
Note: Subjects w ith trans -urethral resection of the prostate or full resection of the 
prostate within [ADDRESS_1037998] 5 y ears.
Note: Patients w ith squamous cell and basal cell carcinoma of the skin are allowed in the 
study.
7Any clinically  significant abnormalit ies in clinical chemistry , hematol ogy, or urinalysis 
resul ts at screening, as judged by  [CONTACT_3170] .
8Any clinically  significant abnormal findings in physical  examinat ion, or vital signs at 
screening, as judged by [CONTACT_3170] .
9Any clinically  significant abnormalit ies on 12 -lead ECG at screening, as judged by  [CONTACT_1275] .
Note: Subjects w ith ECG QTcF interval (corrected for heart rate using Fridericia’s 
formula [QTcF]) > [ADDRESS_1037999] who had severe course of COVID -19 (extracorporeal membrane oxygenat ion, 
mechanically vent ilated, Intensive Care Unit stay ).
14Recent (within 14 days prior to admissio n to the Clinical Unit) exposure to someone who 
has COVID -[ADDRESS_1038000] ion (eg, healthcare worker).
16History  of any respi [INVESTIGATOR_758214], COPD, or idiopathic pulmo nary 
fibrosis.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038001] 
restri ctions will be applied and explained to subjects. Where physical distancing is not 
possible subjects will be asked to use surgical face masks and/or gloves if deemed 
appropriate by  [CONTACT_758231].
19Known or suspected history  of drug abuse, as judged by  [CONTACT_3170] .
20Receipt of any  investi gational drug wi thin 30 days or 5 ha lf-lives (whichever is longer) 
prior to randomizat ion.
Note: subjects consented and screened, but not randomized in this study or a previous 
Phase I study, are not excluded.
21Plasma donat ion within 1 m onth of screening or any  blood donati on/loss m ore than 
500mL during the 3 months prior to screening.
22History  of severe allergy /hypersensi tivity or ongoing allergy/hypersensit ivity, as judged 
by [CONTACT_758232] a similar chemical structure 
or class to BFG .
23Current smokers or those who have smoked or used nicotine products (including 
e-cigarettes) wi thin the [ADDRESS_1038002] John’s Wort within [ADDRESS_1038003] administration of IMP .
26Use of any  prescribed or non -prescribed medication including antacids, analgesics (other 
than parace tamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 
600 times the recommended daily dose) and minerals during the [ADDRESS_1038004] igator .
28Excessive intake of caffeine -containing drinks or food ( eg, coffee, tea, chocolate) as 
judged by  [CONTACT_3170] . Excessive intake of caffeine defined as the regu lar 
consumption of more than 600 mg of caffeine per day ( eg, >5 cups of coffee) or would 
likely  be unable to refrain from the use of caffeine -containing beverages during 
confinement at the invest igational site.
29Involvement of any [COMPANY_008], Parexel or study site em ployee or thei r close rel atives.
30Subjects who have previously received BGF MDI HFO .
31Judgment by [CONTACT_758233] ( ie, during the screening period) mino r medical  com plaints 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038005] itution by [CONTACT_694669].
4.2. Restrictions During the Study
The fo llowing restri ctions apply for the specified times during the study  period:
1On Day 1 of each treatment period, subjects will be fasted for 8hours prior to dosing unt il 
4 hours after dosing. No fluids will be allowed apart from water which can be given unt il 
1hour prior to dosing and then fro m 2 hours after dosing.
2Subjects should n ot lie fully  supi[INVESTIGATOR_050] (unless specified for certain assessments) for [ADDRESS_1038006] 
PK sampling visit. Subjects should also abstain from alcoho l for 72hours before their 
final Fo llow-up Phone Call .
5 S ubjects should abstain fro m caffeine -containing foods and beverages for 24 hours prio r 
to check -in unt il discharge from the Clinical Unit.
6Subjects should abstain fro m grapefruit or grapefruit juice, Seville oranges, quinine 
(eg,tonic water) fro m 7days prior to check -in on Day -[ADDRESS_1038007] be consumed while in the Clinical Unit .
8 S ubjects should abstain fro m consuming high energy  drinks ( eg, Red Bull®), and food 
containing poppy  seeds and any  OTC medicat ion or herbal preparations unt il after their 
final Fo llow-up Phone Call has been completed. Subjects should also limit their caffeine 
intake to equivalent of 3 servings of cof fee per day (1serving = 12 oz soda, 6 oz coffee, 
or 8oz tea). Subjects should consume no more than [ADDRESS_1038008] ions may be implemented based on loc al guidance and/or Clinical 
Unit requirements.
For m edicat ion restrict ions, pl ease refer to Section 5.5.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 35of 974.2.1. Reproductive Restrictions
[IP_ADDRESS]. Women of Non-Child bearing Potential
Women of non -childbearing potential are defined as female subjects who are permanent ly 
surgi cally sterilized or postmenopausal.
Perm anent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral 
salpi[INVESTIGATOR_670042] 6weeks before screening but excludes bilateral tubal ligat ion. Bilateral 
oophorectomy  alone i s acceptable only when the reproductive status of the wom an has been 
confirmed by [CONTACT_36699]-up horm one l evel assessment.
Females are considered postmenopausal if they have had amenorrhea for at least 12 months or 
more following cessation o f all exogenous hormonal treatments and wit hout an alternat ive 
medical cause and the FSH level is in the postmenopausal range.
[IP_ADDRESS]. Women of Childbearing Potential
A wo man is considered of childbearing potential, ie, fertile, fo llowing m enarche and unt il 
beco ming postmenopausal unless permanent ly sterile. Female subjects of c hildbearing 
potenti al must use one highly  effect ive form of birth control . A highly effect ive method of 
contraception is defined as one that can achieve a failure rate of less than 1% per year when 
used consistent ly and correctly . At enrol lment , WOCBP who are sexually active with a 
non-sterilized m ale partner should be stable on their chosen method of highly  effect ive birth 
control , and willing to remain on the birth control unt il at least [ADDRESS_1038009] inence (calendar, symptothermal, post -ovulation methods), withdrawal 
(coitus interruptus), spermicides only , and lactati onal amenorrhea m ethod are not acceptable 
methods of contracepti on. Female condom  and male condom  shoul d not be used together. All 
WOCBP m ust have a negat ive serum pregnancy test result at Screening Visit.
Highly effect ive birth control methods are listed below:
Combined ( estrogen and progestogen containi ng)horm onal contracepti on associ ated wi th 
inhibit ion of ovulation:
Oral
Intravaginal
Transdermal
Progestogen -only horm onal contracepti on associ ated wi th inhibit ion of ovulation:
Oral
Injectable
Implantable
Intrauterine device
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 36of 97Intrauterine horm one-releasing system
Bilateral tubal occlusio n
Vasectomized partner (only acceptable provided that thepartner is the sole sexual partner 
of the subject and that the vasectomized partner has received medical assessment of the 
surgi cal succ ess)
Sexual abst inence defined as co mplete abst inence fro m intercourse when it is the 
preferred and usual lifest yle o f the subject (however, periodic abst inence eg, calendar, 
ovulation, symptothermal, post -ovulation methods, and withdrawal are not acceptab le 
methods of contraception).
Pregnancy Testing
Women of childbearing potential can be included only  after a negative highly  sensi tive serum  
pregnancy test. Addit ionally , serum  or urine pregnancy testing will be done as per the SoA 
(Table 3-1).
Pregnancy
If the subject beco mes pregnant during the study this should be reported to the investigator. 
The invest igator should also be notified of pregnancy occurring during the study but 
confirmed after complet ion of the study . The pregnancy will be followed, and the status of 
mother and/or child will be reported to the sponsor after delivery .
A pregnancy  notificat ion formand fo llow-up will be com pleted.
[IP_ADDRESS]. Male Subjects
There i s no restri ction on fathering children or donating sperm during the study .
4.3. Replacement of Subjects
Subjects who are withdrawn fro m the study  due to any reason will not be replaced.
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 [ADDRESS_1038010] Enrollment and Randomization
The investigator will ensure:
!Signed informed consent is obtained from each potential subject before any study specific 
procedures are performed.
!Each potential subject is assigned a unique enrollment number at screening upon signing 
the Informed Consent.
!The eligibility of each subject is in accordance wi th the inclusion and exclusion criteria.
!Each eligible subject is assigned a unique randomization code.
Randomization codes will be assigned strictly sequentially as subjects become eligible for 
randomization (codes to be used wit hout leading zero(s)). Rando mization num bers will be 
generated within the [COMPANY_008] randomization system (Calyx).
The following specific format must be follo wed for unique enrollment number; reduced 
enrollment number “ ” in ClinBaseTMand on labels, full enrollment number “ ” 
for outputs.
If a subject withdraws his/her participation in the study, then hi s/her enro llment/rando mization
code cannot be reused. For each treatment sequen ce, an additional set of random numbers will 
be generated with Calyx.
5.1.1. Procedures for Randomization
Upon completion of the randomization request form, the rando mization w ill be produced by 
[CONTACT_758234].
The number of subject identifiers generated for the study will account for the number of 
randomized subjects per the sample size calculation (N = 108, see Section 11.4) . For this 
study, a total of n x [ADDRESS_1038011] identifiers w ill be randomly assigned to 1 of 3 possible tr eatment 
sequences: ABB, BAB, BBA, where:
!Treatment A: BGF MDI HFO 160/7.2/4.8 μg ex-actuator; [ADDRESS_1038012] formulation; administered during 1 treatment period.
!Treatment B: BGF MDI HFA 160/7.2/4.8 μg ex-actuator; 4 inhalations as a single dose -
reference formulation; administered during 2 treatment periods.[COMPANY_003] [COMPANY_003]
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038013] to treatm ent (BGF MDI administered with 2 different 
propellants [Treatment A or B] ), ie, the spons or, the invest igator , all clinical staff invo lved in 
the clinical study , the subjects, and the study  monitor will remain blinded, unless safety 
concerns or a regulatory  requi rement necessitate unblinding).
The PK analyst will remain blinded during the stud y conduct.
The PK analyst will be unblinded to perform the final PK analyses after all subjects have 
completed the study , final bioanaly tical resul ts are available and all required study  data are 
considered clean. This may occur prior to database lock.
Thefollowing personnel will have access to the rando mizat ion lists fro m study  start:
The [COMPANY_008] staff carrying out the labelingand packaging of subject specific 
treatm ents.
Pharmacy  staff  preparing the study  medicati on.
Bioanaly tical staff analy zingplasma samples.
The rando mizat ion lists should be kept in a secure locat ion until database lock.
5.3.2. Methods for Unblinding the Study
The treatment code should not be broken, except in medical emergencies when the appropriate 
management of the subject requires knowl edge of  the treatment randomizat ion or regulatory  
requi rements exist (eg, for SAEs). If an emergency unblinding beco mes necessary , the 
investigator should notify the sponsor prior to unblinding, if possible, unless ident ificat ion of 
the IMP i s requi red for em ergency  therapeuti c measures. If a ninvest igator or subject is 
prem aturely  unblinded, the subject m ust be wi thdrawn from  the clinical study  and procedures 
accompanying withdrawal are to be performed. The decisio n to break the blind will be made 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038014] be re corded in 
ClinBase ™and any  associated AE report.
The invest igator will document and report the action to [COMPANY_008] staff.
Details o f the code breaking procedure will be provided in the Safet y Review and 
Management Plan.
5.4. Study Intervention
Study  interven tion is defined as any  invest igational intervent ion(s), m arketed product(s) or 
placebo intended to be administered to or medical device(s) utilized by a study  subject 
according to the CSP.
5.4.1. Investigational Products
Details on the ident ity of the IMPs are presented in Table 5-1.
Table 5-[ADDRESS_1038015] s
Arm Name [CONTACT_758262]/Glycopyronium/ 
Formoterol fumarate pressurized 
inhalation suspension, HFOBudesonide/Glycopyronium/ 
Formoterol fumarate pressurized 
inhalation suspension, HFA 
Type Combination product Combination product
Dose formulation MDI MDI
Unit dose strength(s) 
(delivered dose)160/7.2/4.8 μg per actuation 160/7.2/4.8 μg per actuation
Dosage level 4 inhalations 4 inhalations
Route of administration Oral inhalation Oral inhalation
Use Experimental Comparator
IMP and NIMP IMP IMP
Sourcing Provided centrally by [CONTACT_758235] –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 40of 97Arm Name [CONTACT_758263]. Each MDI will be label edas 
required per country requirements .Study intervention will be provided in 
an MDI. Each MDI will be label edas 
required per country requirements
BGF = budesonide, glycopyrronium, formoterol; HFA = hydrofluoroalkane; HFO = hydrofluoroolefin; 
IMP =investigational medicinal product ; MDI = metered dose inhaler; NIMP = non-investigational medicinal 
product .
Dosing instructions and dispensing details will be provided by [CONTACT_38227].
Budesonide, glycopy rroni um, and form oterol  MDI is a combinat ion product (drug +device).
Details o f thebatch numbers will be included in the Trial Master File and the final CSR.
Subject inhalation training will be performed using the Vitalograph AIM inhalat ion training 
device supplied by  [CONTACT_147029]. As part of this training, subjects will use a placebo Vitalo graph 
HFA MDI. These devices are co mmercially available in many countries, including the [LOCATION_003], 
and used specifically for training with the AIM device. In addit ion to the above, subjects will 
perform  inhalati on training wit h BGF MDI containing placebo (HFA p ropellant based), 
supplied by  [CONTACT_38227]. Per inclusion criterion, subjects must demonstrate the proper 
inhalat ion technique and have the abilit y to properly use an MDI device after training.
Non-IMP supplies will include placebo inhalers for inhalat ion training. Inhalat ion training will 
also be conducted using the AIM training device.
5.4.2. Medical Devices
The [COMPANY_008] manufactured device const ituents’ part of the combination product provided 
for use in this study  are:
Metered dose inhaler (approved)
Instructions for m edical  device use are provided in the Invest igator’s Brochure 2022and 
Combinat ion Products Product of Summary  Characteri stics.
All medical device deficiencies (including malfunction, use error and inadequate label ing) 
shall be documented and reported by  [CONTACT_355649] (see 
Secti on6.3.1.8 ) and appropriately managed by [CONTACT_456].
5.4.3. Supply of Investigational Medicinal Product
The IMPs will be supplied by  [CONTACT_758236] .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038016] to cover all pharmacy related activit ies, detailing roles ,and 
responsibilit ies pri or to recei pt of  the IMP(s) at the Clinical Unit.
A release document signed by a legally  authori zed Q ualified Personin EU/[LOCATION_006] or Pharmacist 
in US Aat the Clinical Unit will be pl aced in the appropriate sect ion of the Trial Master File to 
docum ent labelingand dispensing of the IMP(s) to the subject.
Dispensing and retention of reserve bio equivalence sam ples of IMP will be perform ed in 
accordance with the FDA Code of Federal Regulatio ns 21, Part [ADDRESS_1038017] will receive single doses (4 inhalat ionsas a single dose ) of BGF MDI HFO or 
BGF MDI HFA on Day  [ADDRESS_1038018] will receive 3 single dose treatments of BGF MDI:
Treatment A: BGF MDI HFO 160/7.2/4.8 µg ex -actuator; [ADDRESS_1038019] formulat ion; administered during 1 treatment period.
Treatment B: BGF MDI HFA 160/7.2/4.8 µg ex -actuator; 4 inhalat ions as a single dose -
reference formulation ; administered during [ADDRESS_1038020] 
wear a surgical mask for approximately  30 minutes before and after dosing.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038021] be primed in a separate room (ie, a different room than will be used to 
adminis ter IMP to subjects) by  [CONTACT_758237]. Study  personnel m ust 
wear l aboratory  coats and gl oves during IMP inhaler priming and must remove their 
laboratory  coats and gl oves immediately  after priming is com pleted in the room  where 
primin g was conducted.
At the Screening Visit, on admissio n/Day -1, and pre -dose on Day  [ADDRESS_1038022]’s m outh. The sponsor will provide the Clinical 
Unit with instructions for use. The dosing time (recorded as the time of the fourth inhalat ion) 
must be documented on the eCRF.
5.4.5. Label ing
Bulk labels for IMP will be prepared in accordance with G MP and local regulatory  guidelines. 
The l abels will fulfillGMP Annex [ADDRESS_1038023] -study Treatment(s)
If a subject is being considered for enrollment into the study  and a lso being considered for 
COVID -[ADDRESS_1038024] 
dose of vaccine or booster.
Apart fro m paracetamo l/acetaminophen, hormone replacement therapy , and systemic 
contraceptives, no concomitan t medicat ion or therapy  will be all owed.
The subjects shoul dbe instructed that no other medicat ion is allowed, including herbal 
remedies, vitamin supplements ,and OTC products, without the consent of the invest igator .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038025]’s safet y and well -being, may  be 
given at the discret ion of the investigator during the resident ial period.
When any medicat ion is required, it should be prescribed by [CONTACT_3170] . Following 
consultation wit h [COMPANY_008] Lead Physician, the invest igator should determine whether or 
not the subject should cont inue in the study . Administrati on of  concomi tant m edicat ions that 
may influence the measurement of the PK endpo ints may be doc umented as a CSP deviat ion 
after consul tation of  the invest igator with [COMPANY_008] Lead Physician.
5.6. Study Intervention Compliance
Dosing will take place at the Parexel Early  Phase Clinical Unit.
The administration of all study  intervent ionwill be recorded in ClinBase™.
Com pliance will be assured by [CONTACT_758238]-administrati on of  
study  interventi on.
5.6.1. Drug Accountability, Dispensing, and Destruction
The study  intervent ionprovi ded for thi s clinical study  will be u sed only as directed in the 
CSP.
In accordance with GCP, the Clinical Unit will account for all supplies of BGF MDI HFO and 
BGF MDI HFA . Details of receipt, storage, assembly/dispensing and return will be recorded.
All used and unused supplies of BGF MDI HFO and BGF MDI HFA will eit her be destroy ed 
by [CONTACT_758239] . 
The certificate of delivery  and destructi on m ust be si gned, in accordance with instruction by  
[CONTACT_38227]. De structi on m ust not take pl ace unless the responsible person at [COMPANY_008] 
has approved it.
5.7. Discontinuation of Study Intervention and Withdrawal from 
Study
Dosing for any individual subject will be stopped if the subject experiences a possibly  
drug-related SAE or a possibly drug- related si gnificant non -serious AE, whi ch in the opi[INVESTIGATOR_3078] n 
of the invest igator warrants discont inuat ion of the subject from the act ive CSP for his or her 
well-being.
Healthy subjects m ay be discont inued fro m study  intervent ionin the following si tuations:
Healthy subject decision. The healt hy subject is at any time free to discont inue treatment, 
without prej udice to further treatment.
Severe non -compliance to CSP.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038026] should be encouraged to remain in the 
study  and com plete the rem ainder of the study  visits and procedures. See the SoA ( Table 3-1) 
for data to be collected at the time of discontinuation of study  intervent ion and fo llow-up and 
for any  further evaluat ions that need to be completed.
Note that discontinuation fro m study  intervent ion is NOT the same thing as a withdrawal fro m 
the study .
If a subject experience any of the changes listed below, the study  intervent ion must be 
discontinued:
Development of exclusio n criteria or other safet y reasons as judged by [CONTACT_758240].
Pregnancy or breastfeeding .
Paradoxi cal bronchospasm .
The appropri ate AE form  in the eCRF m ust be completed.
5.7.1. Procedures for Withdrawal of a Subject from the Study
If a subject withdraws or iswithdrawn from  the study , the subject will be encouraged to return 
to the Clinical Unit for an Early Terminat ion Visit to ensure the subjects safet y.
5.8. Premature Termination of the Study
The study  willbe terminated prematurely  if:
The invest igator and the sponsor assess that the number and/or severit y of AEs just ify 
discontinuat ion of the study . 
For instance ,when there is [ADDRESS_1038027] possibly  related to the IMP by  [CONTACT_31374].
The sponsor considers the applied doses of the study drug to be no longer relevant.
The sponsor decides to di scontinue the study .
New data become available and raise concern about the safet y of IMP so that continuat ion 
woul d pose potenti al risks to the subjects.
Prem ature termination o f the study  must be m utually  agreed upon by  [CONTACT_720475]. However, study results will be reported according to the 
requi rements outlined in this CSP as far as applicable.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038028] administration.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038029] measures to assess PK, safet y and tol erabili ty apply during the study . For the single 
doses of BGF MDI planned to be given during this study , no safet y issues are expected.
For timing o f assessments refer to the SoA (Table 3-1).
6.2. Enrol lment and Screening Procedures
Viral serol ogy and urine drugs of abuse, alcohol and cotinine will be assessed for eligibilit y. 
Follicle -stimulating horm one(females only ), pregnancy testing (females only) and use of 
concomitant medicat ion will also be assessed and reported.
6.3. Safety and Eligibility Measurements
Safety and tol erabilit y variables will include:
Adverse events
Vital signs (systolic and diastolic BP, pulse rate, body  temperature, and respi [INVESTIGATOR_2842])
12-lead ECG
Physical examinat ion
Laboratory  assessments ( hematology , clinical  chemistry ,and urinalysis )
6.3.1. Adverse Events
[IP_ADDRESS]. Definition of Adverse Events
An AE is the development of any untoward medical occurrence in a subject or clinical study  
subject administered a medicinal pro duct and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(eg, an abnormal laboratory  finding), symptom (for example nausea, chest pain), or disease 
temporally  associ ated with the use of a m edicinal product, whether or not considered related 
to the m edicinal product.
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may  occur at any  time, including 
run-in or washout periods, even if no study  intervent ion has been administered.
[IP_ADDRESS]. Definitions of Serious Adverse Event
A SAE is an AE occurring during any study  phase (i e, run -in, treatment, washout, fo llow-up), 
that fulfil lsone or m ore of the following criteria:
Results in death .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 47of 97Is immediately life -threatening.
Requi res in -patienthospi [INVESTIGATOR_720457].
Results in persistent or significant disabilit y or incapaci ty or substant ial disrupt ion of the 
abilit y to conduct normal life funct ions.
Is a congenital ano maly or bi rth defect .
Is an important medical event that may jeopardize the subject or may require medical 
intervent ion to prevent one of the outcomes listed above .
For further guidance on the definit ion of a SAE, see Appendix Aof this CSP.
Adverse events for malignant tumorsreported during a study  shoul d gen erally  be assessed as 
SAEs. If no other seriousness criteria apply, the “Important Medical Event” criterion should 
be used. In certain situat ions, however, medical judgment on an individual event basis should 
be applied to clarify that the malignant tumorevent should be assessed and reported as a 
non-serious AE. For example, if the tumoris included as medical history and progression 
occurs duri ng the study , but the progression does not change treatment and/or prognosis of the 
malignant tumor, the AE may  not fulfillthe attributes for being assessed as serious, although 
reporting of the progression of the malignant tumoras an AE is valid and should occur. Also, 
some ty pes of  malignant tumors, which do not spread remotely after a routine treatment that 
does not require hospi[INVESTIGATOR_3094], may be assessed as non -serious; examples include Stage 1 
basal cell carcino ma and Stage 1A1 cervical cancer removed via cone biopsy.
[IP_ADDRESS]. Other Significant Adverse Events
During the evaluat ion of the AE data, an [COMPANY_008] medical
ly qualified expert will review 
the list of AEs that were not reported as SAEs or where relevant DAEs and withdrawal fro m 
the study . Based on the expert’s judgment, significant AEs of particular clinical importance 
may, after consultat ion with the Gl obal S afety Physician, be considered OAEs and reported as 
such in the CSR. A similar review of other data from laboratory  tests, vi tal signs, ECGs, and 
other safet y assessments will be performed for ident ification o f OAEs.
Examples of these are marked hematol ogicand other laboratory  abnorm alities, and certain 
events that lead to intervention (other than those already  classified as serious), dose reduction 
or significant addit ional treatment.
[IP_ADDRESS]. Recording of Adverse Events
Time Period for Collection of Adverse Events
Adverse events will be collected from the start of screening throughout the treatment period 
up to and including the Fo llow-up Phone Call .
Serious adverse events will be recorded from the time of informed consent.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038030]’s last visit in the study  are f ollowed up by  [CONTACT_379294], but without further recording in ClinBase™ .
[COMPANY_008] retains the right to request additional informat ionfor any  subject wi th ongoing 
AE(s)/SAE(s) at the end of the study , if judged necessary .
Variables
The fo llowing variables will be collected for each AE:
AE term  (diagnosis/verbatim)
The date and time when the AE started and stopped
Intensit y
Whether the A E is seri ous or not
Invest igator causalit y rating against the IMP (yes or no)
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for seri ous AE
Date invest igator became aware of serious AE
Adverse event is seriou s due to
Date of hospi[INVESTIGATOR_059]
Date of discharge from hospi[INVESTIGATOR_307]
Probable cause of death
Date of death
Autopsy  performed (y es/no)
Causalit y assessment in relat ion to study  procedure(s)
Causalit y assessment to other medicat ion'
The fo llowing intensit y ratings will be used:
Mild (awareness of sign or symptom, but easily tolerated).
Moderate (di scomfort sufficient to cause interference with normal act ivities).
Severe (incapacitat ing, with inabilit y to perform  norm al activities).
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038031] inguish between serious and severe AEs:
Severit y is a measure of intensit y whereas seriousness is defined by [CONTACT_720478]6.3.1.2 .
An AE of severe intensit y need not necessarily be considered serious. For example, 
nausea that persists for several hours may be considered severe nausea, but not a SAE. On 
the other hand, a stroke that results in only a limited degree of disabilit y may be 
conside red a mild stroke but would be an SAE.
Causality Collection
The invest igator will assess causal relat ionship between IMP and/or i nvest igational medicinal 
devices and each AEs and/or incident, and answer “yes” or “no” to the question “Do y ou 
consider that there is a reasonable possibilit y that the event may  have been caused by [CONTACT_33155]?”
For SAEs ,causal relat ionship will also be assessed for other medicat ion, any addit ional drug 
and study  procedures. Note that for SAEs that could be asso ciated wi th any study  procedure 
the causal relat ionship is implied as “yes”.
A guide to the interpretation of the causalit y quest ion is found i n Appendix Aof this CSP. For 
medical devices, a guide to the interpretation of the causalit y questi on can be found in
Appendix D.
Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by  [CONTACT_758241]: “Have you had any health proble ms since you w ere last asked?” or 
revealed by  [CONTACT_758242]™.
When co llecting AEs, the recording of diagnoses is preferred (when possible) to recording a 
list of signs and symptoms.
However, if a diagnosis is known and there are other signs or symptoms that are not generally 
part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.
Adverse Events Based on Examinations and Tests
The results from CSP-mandated laboratory  tests, vital sig ns, ECGs ,and other safet y 
assessments will be summarized in the CSR.
Deteri oration as com pared to baseline in CSP-mandated laboratory  values, vital signs, ECGs ,
and other safet y assessments should therefore only be reported as AEs if they fulfill any of t he 
SAE cri teria or are the reason for discont inuat ion of treatm ent wi th the IMP or are considered 
to be clinically relevant as judged by  [CONTACT_3170] (which may include, but not limit ed to, 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038032] ment or drug interruption).
If deteri oration in a laboratory  value or vi tal sign is associ ated wi th clinical  signs and 
symptoms, the sign or symptom will be reported as an AE and the associated laboratory  resul t, 
or vital sign will be considered as additional informat ion.
Wherever possible the reporting invest igator should use the clinical, rather than the laboratory 
term (eg, anemia versus low Hbvalue).
In the absence of clinical signs or symptoms, clinically relevant deteriorations in 
non-CSP-mandated param eters shoul d be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE.
Hy's Law
Cases where a subject shows elevat ion in liver bio chemistry  may require further evaluat ion 
and occurrences o f AST or ALT ≥ [ADDRESS_1038033] together with TBL ≥ [ADDRESS_1038034] may  need to be 
reported as SAEs. Please refer to Appendix Cfor further instruction on cases of increases in 
liver biochemistry  and evaluat ion of Hy’s Law.
Adverse Events Associated with Use of ICS, LAMAs, and LABAs
Certain AEs have been ident ified as associated to the class of drugs being studied. Known 
effects of LAMAs and LABAs include cardiovascular effects, ocular disorders, urinary 
retenti on, gastrointestinal disorders, and ant icholinergic effects for LAMAs and 
cardi ovascular and tremor effects for LABAs. Local corticosteroid eff ects include oral 
candidiasis, hoarseness, oropharyngeal candidiasis, dy sphonia, and throat irritation. Sy stemic 
corticosteroi d effects include fractures, osteoporosis/osteopenia, adrenal suppressio n, and 
adrenal cortical hypo functions. These AEs will be c aptured as described and presented in 
summary tabulation in the CSR.
[IP_ADDRESS]. Reporting of Serious Adverse Events
All SAEs have to be reported, whether or not considered causally related to the IMP, or to the 
study  procedure(s). All SAEs will be recorded in ClinBase™.
If any SAE occurs in the course of the study , then the invest igator or other site personnel will 
inform  appropri ate [COMPANY_008] representatives immediately, or no later than 24 hours of 
when he or she beco mes aware of it.
The designated AstraZen eca representative will work with the investigator to ensure that all 
the necessary information is provided to the [COMPANY_008] pat ient safet y data entry  site within 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038035] igators or other site personnel will inform [COMPANY_008] representati ves of any fo llow-up 
inform ation on a previously  reported SAE immediately, or no later than 24 hours of when he 
or she beco mes aware of it.
If the EDC system is not available, then the investigator or other study  site staff reports a SAE 
to the appropriate [COMPANY_008] representative by [CONTACT_756].
The [COMPANY_008] representative will advise the investigator /study site staff how to proceed.
The reference document for definit ion of expectedness/listedness is the IB for the [COMPANY_008] 
drug.
[IP_ADDRESS]. Regulatory Reporting Requirements for Serious Adverse Events
Prom pt notificat ion by [CONTACT_32847] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y ofsubject s and the safet y of a study  
intervention under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal Regulatory  Authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply with country -specific regulatory  requi rements relating to safet y reporti ng 
to the Regulatory  Authori ty, IRB, and investigators.
For all studies, invest igator safet y reports m ust be prepared for S[LOCATION_003]Rs according to local 
regul ations (for studies utilizing me dical  devices –according to European Medical Device 
Regulation 2017/745 for clinical device research )and sponsor policy  and f orwarded to 
investigators as necessary .
Aninvest igator who receives an invest igator safety report describing a SAE or other spec ific 
safet y informat ion (eg, summary  or list ing of SAEs) fro m the sponsor will review and then 
file it along wit h the IB and will notify the IRB, if appropriate according to local 
requi rements.
[IP_ADDRESS]. Medical Device- related Safety Events
The definit ions of medical device -related safet y events can be found in Appendix D. Medical  
Device deficiencies are covered in Sect ion6.3.1.8 .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 52of [IP_ADDRESS]. Medical Device Deficiencies
Drug/device co mbination products are being provided for use in this study .In order to fulfil l
regul atory  reporting obligations worldwide , the investi gator i s responsible for the detection 
and docum entati on of  events m eeting the definit ions of medical device deficiency  that occur 
during the study  with such medical devices.
The definit ion of a medical device deficiency  for device constituent of a combinat ion product 
is an inadequacy of a medical device with respect to its ident ity, qualit y, durabilit y, reliabilit y, 
safet y, or perform ance. Medical device deficiencies include malfunct ions, use errors, and 
inform ation supplied by [CONTACT_63733] r.
The [COMPANY_008] medical device co mplaint report will be used to collect the deficiency.
NOTE: Incidents and deficiencies fulfilling the definit ion of an AE/SAE will also fo llow the 
processes outlined in Appendix Dof the CSP.
[IP_ADDRESS].1. Time Period for Detecting Medical Device Deficiencies
Medical device incidents or malfunct ions of the medical device will be detected, 
docum ented, and reported during all periods of  the study  in which the medical device is 
used.
If the invest igator learns of any medical device deficiency at any t ime after a subject has 
been discharged from the study , and such incident is considered reasonably related to a 
medical device pro vided for the study , the investigator will pro mptly notify  the sponsor.
The m ethod of docum enting medical  device deficiency is provided in Appendix D.
[IP_ADDRESS].2. Follow-up for Medical Device Deficiencies
Follow-up applies to all subjects, including those who discont inue study  intervent ion.
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucida te the nature and/or causalit y of the deficiency.
New or updated informat ion will be recorded on the originally co mpleted form wit h all 
changes signed and dated by  [CONTACT_093].
[IP_ADDRESS].3. Prompt Reporting of Medical Device Deficiencies to Sponsor
Medical device deficiencies will be reported to the sponsor within 24 hours after the 
investigator determines that the event meets the CSP definit ion of a medical device 
deficiency.
The medical  device deficiency Paper Report Form will be sent to the sponsor by  [CONTACT_6968] . If 
emailis unavailable, then telephone shoul d be utilized.
The sponsor will be the contact [CONTACT_244971].
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 53of [IP_ADDRESS].4. Regulatory Reporting Requirements for Device Deficiencies
The invest igator will pro mptly report all medical device deficiencies occurring with any  
medical device provided for use in the study  in order for the sponsor to fulfil lthe legal 
responsibilit y to notify appropriate regulatory  authori ties and other entit ies about certain 
safet y informat ion relating to m edical devices being used in clinical studies.
The invest igator , or responsible person according to local requirements (eg, the head o f 
the medical inst itution), will co mply with the applicable local regulatory  requi rements 
relating to the reporting o f medical device deficiencies to the IRB.
For further guidance on the definit ion of an SAE, see Appendix Dof the CSP.
6.3.2. Laboratory Assessments
[IP_ADDRESS]. Hematology
Hematology
White blood cell (WBC) count Neutrophils absolute count 
Red blood cell (RBC) count Lymphocy tes absolute count 
Hemoglobin (Hb) Monocytes absolute count 
Hematocrit (HCT) Eosinophils absolute count 
Mean corpuscular volume (MCV) Basophils absolute count 
Mean corpuscular hemoglobin (MCH) Platelets
Mean corpuscular hemoglobin concentration (MCHC) Reticulocytes absolute count 
[IP_ADDRESS]. Serum Clinical Chemistry
Serum Clinical Chemistry
Sodium Alkaline phosphatase (ALP)
Potassium Alanine aminotransferase (ALT)
Urea Aspartate aminotransferase (AST)
Creatinine Gamma glutamyl transpeptidase (GGT)
Albumin Total Bilirubin (TBL)
Calcium Unconjugated bilirubin
Phosphate Follicle -stimulating hormone (FSH)b
Glucose (fasting) Thyroxine (T 4) a
C-reactive protein (CRP) Thyroid stimulating ho rmone (TSH)a
aScreening only
bPostmenopausal women
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 54of [IP_ADDRESS]. Urinalysis
Urinalysis
Glucose Protein
Blood
Microscopy (if positive for protein or blood): RBC, WBC, Casts (Cellular, Granular, Hyaline)
[IP_ADDRESS]. Pregnancy Testing
Pregnancy test (females only)
Human -beta chorionic gonadotrophin
[IP_ADDRESS]. Viral Serology
Viral Serology
Human immunodeficiency virus (HIV) I and II Hepatitis C Virus antibody
Hepatitis B surface antigen (HBsAg)
[IP_ADDRESS]. Drugs of Abuse, Alcohol and Cotinine
Drugs of Abuse ,Alcohol , and Cotinine Testing
Amphetamine (AMP) /Ecstasy Benzodiazepi[INVESTIGATOR_1651] (BZO)
Ethanol Methadone Metabolites (MTD)
Cannabinoids Barbiturates (BAR)
Cocaine (COC) Phency clidine (PCP)
Opi[INVESTIGATOR_858] (OPI) Urine Creatinine
CotinineaMethy lenedioxy methamphetamine (MDMA)
Tricyclic anti -depressants (TCA) Oxycodone (OXY)
Bupreno rphine (BUP)
Methamphetamine (MET)
aScreening only
Drugs of abuse screen will be done via a urine sample. Alcoho l screen will be done via a 
serum  sample.
[IP_ADDRESS]. COVID -19 Testing
COVID -19 Testing (Nasopharyngeal Swab)
SARS -CoV -2 RT -PCR Rapid SARS -CoV -2 done at admission
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 55of 976.3.3. Physical Exa mination
Full
The complete physical examinat ions will include an assessment of the general appearance, 
respi [INVESTIGATOR_696] , cardi ovascular, abdo men, skin, head, and neck (including ears, ey es, nose, and 
throat), lymph nodes, thy roid, muscul oskeletal  and neurological systems.
Brief
The brief physical examinat ions will include an assessment of the general appearance, skin, 
abdo men, cardi ovascula r, and respi [INVESTIGATOR_36517] .
6.3.4. Electrocardiograms
Safety 12-lead ECGs will be perform ed at the time points specified in the SoA ( Table 3-1).
Safety 12-lead ECGs will allow the site invest igator to review the ECG tracings at bedside and 
determine any  potenti al abnorm alities and risks.
[IP_ADDRESS]. Safety 12-lead ECGs
A [ADDRESS_1038036] 5 minutes at all t imepoints listed in SoA ( Table 3-1) and whenever 
it is requi red by [CONTACT_3170]. All ECGs will be evaluated with respect to rhy thm; heart 
rate; and PR, RR, QRS, QT, and QTcF intervals from the 12 -lead safet y ECG, and the 
investigator will judge the overall interpretation as normal or abnormal. If abnormal, it will be 
decided whether the abnormalit y is clinically significant or not, and the abnormalit y will be 
recorded. The investigator or delegate will evaluate the safet y ECG in real t ime.
The date/time and the physician interpretation (normal, abnormal clinically significant, 
abnorm al not clinically  significant) for the safet y ECGs will be recorded in the ClinBase™ 
and stored as source documents.
6.3.5. Vital Signs
The fo llowing variables will be collected after the subject has rested in the supi[INVESTIGATOR_226354] 5 minutes:
Systolic BP (mmHg)
Diastoli c BP (mmHg)
Pulse rate (beats per minute [bpm])
Body  temperature (°C)
Respi[INVESTIGATOR_2842] (breaths per minute )
The m easurement of vital signs will be carried out according to the relevant Parexel SOPs.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038037] or a qualified designee to ensure subjects 
achieve optimal lung function and using standardized equipment that meets or exceeds the 
ATS/ERS jo int recommendat ions.
The subject will be in a seated posit ion during spi[INVESTIGATOR_038] . The fo llowing variables will be 
record ed:
Forced expi[INVESTIGATOR_131955]
Forced expi[INVESTIGATOR_758215]
Forced vital capacit y
FEV1/FVC ratio
Spi[INVESTIGATOR_325338] m eet both acceptabilit y and repeatabilit y criteria according to ATS/ERS 
2019 recommendations ( Graham etal.2019 ). Cal culated predicted spi[INVESTIGATOR_758216] (Quanjer etal.2012 ).
6.4. Pharmacokinetics
6.4.1. Collection of Pharmacokinetic Samples
[IP_ADDRESS]. Plasma Samples
Blood sam ples f or the determination of plasma concentrations of budesonide, 
glycopy rroni um,and form oterol will be collected for each treatment period as specified in the 
SoA(Table 3-1).
Samples will  be collected, handled, label ed, stored ,and shipped as detailed in the Laboratory  
Manual.
6.4.2. Pharmacokinetic Drug Assays
Blood sam ples f or determinat ion of budesonide, glycopy rroni um, and form oterol  
concentrations in plasma will be analy zedby [CONTACT_758243] o f [COMPANY_008], using a 
validated assay. Addit ional analyses m ay be conducted on the bio logical  samples to further 
investigate the presence and/or ident ity of drug m etaboli tes.
Full details o f the analy tical method and analyses performed will be described in a separate 
bioanaly tical report.
6.5. Pharmacodynamics
Not applicable .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 57of 976.6. Pharmacogenetics
Not applicable .
6.7. Biomarkers
Not applicable .
6.8. Immunogenicity
Not applicable .
6.9. Metabolites
Not applicable .
6.10. Taste Assessment
Not applicable .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 58of 977. BIOLOGICAL SAMPLES P ROCEDURES
All biological samples will be collections will be performed by  [CONTACT_758244]’s SOPs .
7.1. Total Blood Volume
The m aximum  volume to be drawn from  each subject, including repeat samples, must not 
exceed 500 mL in total in any 55-day peri od of  a study .
7.2. Handling, Storage ,and Destruction of Biological Samples
Samples will  be disposed of, on instruction from [COMPANY_008], after the CSR has been 
finalized, unless samples are retained for addit ional or future analyses.
7.2.1. Pharmacok inetic Samples
Pharmacokinet ic samples will be disposed of after the bioanalyt ical report finalizat ion or 
6months after issuance of the draft bioanaly tical report (whi chever is earlier), unless 
requested for future analyses.
Pharmacokinet ic samples may be disposed of or anonymized by [CONTACT_76435]. Addit ional analyses 
may be conducted on the anonymized, pooled and/or individual PK samples to further 
evaluate and validate the analyt ical method. Any  resul ts from such analyses may be reported 
separately  from the CSR .
Incurred sample reproducibilit y analysis, if any , will  be perform ed al ongside the bioanalysis 
of the test samples. The results from the evaluation will not be reported in the CSR but 
separately  in a bi oanaly tical report.
7.3. Labelingand Shipment of Biohazard Samples
Samples will  be label edand shipped in accordance with the Laboratory  Manual and the 
Biological Substance, Category  B regul ations (materials containing or suspected to contain 
infect ious substances that do not meet Category A criteria), se e Appendix Bof this CSP
‘IATA 6.2 Guidance Document’.
Any samples ident ified as Infect ious Category  A materi als will not be shipped and no further 
samples will be taken from the subject unless agreed with [COMPANY_008] and appropriate 
label ing, shipment and containment provisio ns are approved.
7.4. Chain of Custody of Biological Samples
A full chain o f custody  will be m aintained for all sam ples throughout their lifecycle.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038038] igator will ensure full traceabilit y of collected bi ological samples from  the subjects 
while in storage at the Clinical Unit until shipme nt and will keep documentation of receipt of 
arrival.
The sample receiver will keep full traceabilit y of samples while in storage and during use, 
until used, disposed of, or until further shipment or disposal (where appropriate) and will keep 
docum entati on of  receipt of arrival.
Samples retained for further use will be registered in the [COMPANY_008] bio bank system during 
the ent ire life cycle.
7.5. Withdrawal of Informed Consent for Donated Biological Samples
If a subject withdraws consent to the use of donated bio logical samples, the sam ples will  be 
disposed if not al ready  analy zedand the acti on docum ented.
As collect ion of donated bio logical samples is an integral  part of the study  then the subject is 
withdrawn from  further study  parti cipat ion.
[COMPANY_008] ensures the central laboratory (ies) ho lding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of/destroy ed, the acti on 
docum ented, and the signed document returned to the Clinical Unit.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 60of 978. REGULATORY AND ETHICAL CONSIDERATIONS
8.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the CSP and with the fo llowing:
Consensus ethical principles derived from in ternational  guidelines including the 
Declaration of Helsinki (Fortal eza, Brazil, October 2013) and Council for 
International Organizat ions of Medical Sciences Internati onal Ethical  Guidelines
Applicable ICH GCP Guidelines
Applicable laws and regulations
The CSP, CSP amendments, ICF, IB, and other relevant documents (eg, advertisements) 
must be submitted to an IRB by [CONTACT_758245].
Any amendments to the CSP will require IRB and applicable Regulatory  Authori ty 
approval  before implementati on of  changes made to the study  design, except for changes 
necessary  to eliminate an immediate hazard to study  subjects.
[COMPANY_008] will be responsible for obtaining the required authori zationsto conduct t he 
study  from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
CRO ,but the accountabilit y remains wi th [COMPANY_008].
The invest igator will be responsible for providing oversight of the conduct of the study at 
the site and adher ence to requirements of 21 CFR, ICH guidelines, the IRB, European 
Regulation 536/2014 for clinical studies (if applicable), European Medical Device 
Regulation 2017/745 for clinical device research (if applicable), and all other applicable 
local regulati ons.
8.2. Data Protection
Subjects will be assigned a unique ident ifier. Any subject records or datasets that are 
transferred to the sponsor will contain the identifier only; subject names or any  
inform ation which would make the subject ident ifiable will not be transferred.
The subject must be informed that his/her personal study -related data will be used by  [CONTACT_32855] h local data protecti on law. The l evel of disclosure and use of 
their data m ust al so be explained to the subject in the informed consent .
The subject must be informed that his/her medical records may be examined by [CONTACT_32856] y Assurance auditors or other authorized personnel appo inted by  [CONTACT_456], by  
[CONTACT_42506], and by [CONTACT_6668].
All clinical study  findings and documents will be regarded as confident ial. The invest igator 
and members of his/her research team must not disclose such information wit hout pri or 
written approval  from the sponsor.
The anonymit y of participating subjects must be maintained. Subjects will be specified in 
outputs and other documents containing subject data by  [CONTACT_139927], not by  [CONTACT_2300]. 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038039] ( eg, signed ICF) will be maintained in confidence by [CONTACT_1275] .
Study  data will be stored in accordance with local and glo bal data protection laws.
8.3. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study to the 
subject or his/her legally authori zedrepresentative and answer all q uesti ons regarding the 
study .
Subjects m ust be informed that their participation is voluntary ,and they  are f ree to refuse 
to parti cipate and may  withdraw thei r consent at any  time and for any  reason during the 
study . Subjects or their legally  authori zedrepresentative defined as ‘an individual, or 
judicial, or other body  authorized under applicable law to consent on behalf of a 
prospective subject to the subject's participat ion in the procedure(s) involved in the 
research’, will be required to sign a state ment of informed consent that meets the 
requi rements of [ADDRESS_1038040] of 1996 requirements, where applicable, and the IRB 
or Clinical Unit.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the subject was enro lled in the study  and the date the written consent was ob tained. 
The authori zedperson obtaining the informed consent must also sign the ICF.
Subjects m ust be re -consented to the most current versio n of the ICF(s) during their 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the subject or the subject’s legally  authori zed
representative.
Subjects who are rescreened are required to sign a new ICF.
8.4. Insurance
The sponsor has covered this clinical study  by [CONTACT_3163] o f an insurance of the clinical study  
according to national requirements. The name [CONTACT_758264], 
the certificate of insurance, the policy number and the sum insured are provided in the 
Invest igator's Site File.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038041] and confident iality of the data.
Internal qualit y control  will be performed at all stages of the study  by [CONTACT_758246] t.
9.2. Audit/Inspections
The Clinical Unit facilit ies and all study  data/documentati on m ay be audi ted/inspected by  
[CONTACT_718163]/inspector/any  representatives of regulatory  authori ties. The invest igator
must allow the applicable persons access to all relevant facilit ies and data/documents. The 
investigator must be available to discuss any findings/issues.
If an audit was performed, the audit certificate will be included in the CSR.
9.3. Study Moni toring
The conduct of the study  will be m onitored by  [CONTACT_758247]. The summary of the 
docum entati on of  the m onitoring visi ts will form part of the study  docum entati on an d will  be 
archived as such.
9.4. Data Collection
The ClinBase™ system is an electronic source data capturing and informat ion management 
system . The system  combines all aspects of source data capturing with process control and 
clinical study  management. All clin ical and laboratory  data, except those which are 
paper -based or provided by [CONTACT_720491], will be collected in ClinBase™. Only 
paper -based data will be subject to data entry . For el ectroni c source data, no data entry  will be 
perform ed.
The responsible study  monitor will  check data at the mo nitoring visits to the Clinical Unit. 
The invest igator will ensure that the data collected are accurate, complete ,and legible. Data 
will be mo nitored wi thin ClinBase™ by  [CONTACT_720492]. Any  
changes made during monitoring will be documented with a full audit trail wit hin ClinBase™.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038042] ion methods during the clinical study  will be recorded in 
ClinBase™. All source docum ents fro m which ClinBase™ entries are derived should be 
placed in the subject’s personal records.
The ori ginal  ClinBase™ entri es for each subject will be checked against source documents by 
[CONTACT_10184]. Instances of missing or uninterpret able data will be discussed with the 
investigator for resolution.
9.4.2. Access to Source Documents
During the course of the clinical study , a study  monitor will  make Clinical Unit visit s to 
review CSP compliance, com pare ClinBase™ entries and individual subject’ s personal 
records, assess IMP accountabilit y and ensure that the clinical study  is being conducted 
according to pertinent regulatory  requi rements. ClinBase™ entries will be verified against 
source documents. The review of medical records will be handled c onfidentially to ensure 
subject anonymit y.
Checking of the ClinBase™ entries for completeness and clarit y and verifying wit h source 
docum ents, will be required to monitor the clinical study  for com pliance wi th GCP and other 
regul ations. Moreover, regulator y authori ties of certain countries, IECs/IRBs may  wish to 
carry  out source data inspect ions on site, and the sponsor ’s clinical qualit y assurance group 
may wish to carry  out audi ts. Di rect access to source data will be required for these 
inspections and au dits; they  will be carri ed out giving due consideration to data protection and 
subject confident iality. The invest igator assures the sponsor of the necessary  support at all 
times.
9.5. Data Management
Parexel will utilize standardized and validated procedures a nd systems to collect, process and 
file the clinical data of this study . Any system  used will be com pliant wi th FDA [ADDRESS_1038043] be finalized before data validat ion.
After the data has been monitored by  [CONTACT_720493], logged ,and filed.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038044] a full audit trail.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038045]. A 
treatm ent emergent adverse event is defined as an AE with onset (start date/time) after dosing 
the first dose of IMP in Treatment Period 1 .
Adverse events will be assigned to a treatment based on the start date/time of the AE in 
relation to dosing in that period; for tabulat ion purposes t he AE will then be assigned to the 
treatm ent received in the respective treatment period as fo llows:
Screening: all AEs with start date/time prior to dosing in Treatment Period 1.
Treatment Period 1: AEs with start date/time at the time of or after dosing in Treatment 
Period 1 un til the time of dosing in Treatment Period 2.
Treatment Period 2: AEs with start date/time at the time of or after dosing in Treatment 
Period 2 un til the time of dosing in Treatment Period 3.
Treatment Period 3: AEs with start date/ time at the time of or after dosing in Treatment 
Period 3 un til the final Fo llow-up Phone Call .
Adverse events with missing start dates/times will be handled as fo llows:
If the start date is co mpletely missing but the end date is known and shows that the AE 
ended on or after the first dose date, then the start date will be imputed as the first day  of 
dosing; if the end date is known and shows that the AE ended before the first dose date, 
then the screening date will be used for the start date. If the end d ate is non -informative 
(ie, is missing or does not contain enough informatio n), the start date will be imputed as 
the first date of dosing .
If only  the start day  is missing the day  will be imputed as the first day  on which a dose 
was given in that month un less the end date is known and shows that the AE ended before 
a dose was given in that month; in which case the date will be imputed as 01. If the end 
date i s non -informat ive (ie, is missing or does not contain enough information), the start 
date will be imputed as the first date of dosing in the known month. If the month is not a 
dosing mo nth the date will be imputed as 01 .
If the start day  and m onth are missing the date will be imputed as the first day  of dosing 
in the known year unless the end date is kn own and shows that the AE ended before a 
dose was given in that y ear; in which case the start day  and m onth will be imputed as 
01Jan or with the date of screening if this is later. If the end date is non -informat ive (ie, is 
missing or does not contain enou gh informat ion), the start date will be imputed as the first 
date of dosing in the known y ear. If the y ear is not a y ear of dosing, then the date will be 
imputed as 01Jan or with the date of screening if this is later.
Missing times will be imputed as 00:0 0 h or with the time o f dosing for events starting on 
a dosing day .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 66of 97Adverse events will be summarized by [CONTACT_3148] (where treatments will be pooled across 
treatm ent peri ods) and overall for all subjects, including tabulations by [CONTACT_20084] y and severit y 
(mild, moderate ,and severe). All tabulat ions will be presented by [CONTACT_9315]. 
Furtherm ore, separate list ings of SAEs, DAEs , and AEs that led to death will be presented.
The fo llowing inform ation will be included in the list ings: verbat im term, SOC, preferred term
and lowest l evel term , start date/time, end date/time, time from last dose, causalit y, action 
taken, whether the AE was classified as serious ,and the outcome.
All tabulat ions will include the number and percentage of subjects. In addit ion,a separate 
tabul ation will be presented showing the number of events by  [CONTACT_758248].
Finally ,an overview of all AEs will be presented, separately  for the numb er and percentage of 
subjects and the number of events. This will include categories for any AE, AEs with outcome 
of death ,and SAEs.
10.1.2. Laboratory Assessments
Hem atologyand clinical chemistry  values will be listed by  [CONTACT_758249]/unscheduled measurements. Summary tabulat ions including 
absolute values and changes fro m baseline will be presented by [CONTACT_758250] y 
analysis set. The baseline for the measurements will be the screening assessment perf ormed 
prior to dosing in Treat ment Period 1. Shift tables will also be presented.
The list ings will include the fo llowing informat ion: test name, date of measurement, reference 
range, result and flags for any measurements that are outside the reference ran ge (eg, 
[COMPANY_008], program, or laboratory ranges). Clinical laboratory  data will be reported in 
System  Internat ional units in the CSR.
Addit ional listings will be presented for the fo llowing:
Urinalysis (macroscopic and microscopic, if applicable) .
Pregnancy testing (including FSH) .
The results of viral sero logy and the drugs of abuse and alcohol screen will not be listed 
in the CSR.
10.1.3. Physical Exa mination
The baseline/screening results o f the physical examinat ion will be documented in medical 
history for each subject.
Any new or aggravated clinically relevant abnormal medical physical examinat ion finding 
compared to the baseline assessment will be reported as an AE.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038046] igator as 
“Norm al”, “Abnorm al CS” (clinically  significant) and “Abnormal NCS” (not clinically 
significant) .
10.1.5. Vital Signs
The results of the vital signs measurements will be listed by [CONTACT_758251] e/time of the assessment, changes fro m baseline and repeat/unscheduled measurements. 
The baseline for vital signs measurements will be the screening assessment. Descript ive 
statist ics will be presented by [CONTACT_758252] a nd changes 
from baseline.
10.2. Pharmacokinetic Variables
Where possible, the PK parameters will be assessed for budesonide, glycopy rroni um,and 
formoterol using pl asma concentrations .
10.2.1. Plasm aParameters
Primary PK parameters
AUCinf Area under plasma concentration -time curve from zero to infinity
AUClast Area under the plasma concentration -curve from zero to the last quantifiable 
concentration
Cmax Maximum observed plasma (peak) drug concentration
Secondary PK parameters
tmax Time to reach peak or maximum observed concentration or response following 
drug administration
t½λz Half-life associated with terminal slope (λz) of a semi -logarithmic 
concentration -time curve
MRT inf Mean residence time of the unchanged drug in the systemic circulation from zero 
to infinity
λz Terminal rate constant, estimated by [CONTACT_26500] -linear least squares regression of the 
terminal part of the concentration -time curve
CL/F Apparent total body clearance of drug from plasma after extravascular 
administration
Vz/F Volume of distribution (apparent) at steady state following extravascular 
administration (based on terminal phase)
Addit ionally , Test (Treatm ent A) to Reference (Treatment B) ratios for AUCinf, AUClast ,and 
Cmax will  be calculated for each individual subject.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 68of 97The following di agnostic param eters f or plasma PK analysis will be listed, but not 
summarized:
λz upper and λz lower The time interval (h) of the log-linear regression to determine t ½
λzN Number of data points used for λz determination
Rsq_adj Statistical m easure of fit for the regression used for λz determination adjusted for 
the number of used data points (n obs)
AUCextr Extrapolated area under the curve from tlast to infinity, expressed as percentage 
of AUCinf
Addit ional PK parameters may  be determined where appropriate.
10.2.2. Calculation or Derivation of Pharmacokinetic Param eters
The PK analyses of the plasma concentration data for budesonide, glycopy rronium ,and 
formoterol  will be performed by [CONTACT_38227] R&D.
PK parameters will be derived using non -compar tmental  methods with Phoenix® 
WinNonlin® Versio n 8.2, or hi gher. All descript ive and inferent ial statistical co mputations 
will be performed using SAS® Versio n 9.4, or hi gher.
PK analysis will, where possible, be carried out using actual times recorded in t he raw data. If 
actual t imes are missing, no minal t imes will be used.
Plasma concentrations which are NQ prior to the first quantifiable concentration will be set to 
a value of zero. After the first quantifiable concentration, any NQ plasma concentrations will 
be set to missing for all concentration profiles. Where [ADDRESS_1038047] ic of the profile of the drug.
If an entire concentration- time profile is NQ, the profile will be excluded fro m the PK 
analysis.
Terminal eliminat ion half-life, cal culat ed as (ln2)/λz, will be est imated by [CONTACT_26500] -linear least 
squares regressio n of the terminal part of the concentration -time curve. For the determinat ion 
of λz, the start of the terminal eliminat ion phase for each subject will be defined by  [CONTACT_758253] d will be the first point at which there is no systemat ic deviation fro m the 
log-linear decline in plasma concentrations. A minimum o f [ADDRESS_1038048] + C last/λz where Clast 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038049] quantifiable drug concentration. The AUC infvalues where the percentage 
extrapol ation is greater than 20% will be flagged in the data list ings.
AUCs (including AUC infand AUClast) will be calculated using the linear trapezoi dal method 
when concentrations are increasing and the logarithmic trapezoidal method when 
concentrations are decreasing.
The minimum requirement for the calculat ion of AUC will be the inclusio n of at least 
3consecutive plasma concentrations above the LLOQ, wi th at least 1 of these concentrations 
following Cmax.
10.3. Pharmacodynamic Variable(s)
Not applicable .
10.4. Pharmacogenetics
Not applicable .
10.5. Exposure -Response Analyses
Not applicable .
10.6. Taste Assessment
Not applicable .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038050] the analysis o f the PK data.
Subjects m ay be excl uded f rom the PK analysis set as a result of the following:
Data from subjects for whom the pre -dose concentration is > 5% of Cmax for BGF MDI 
in a specific treatm ent period .
A subject m ay be excluded from  the analysis only  for the specific treatm ent peri od in which 
the AE occurred.
The exclusio n of any  subjects o r time points from the calculat ion of the PK parameters will be 
docum ented by  [CONTACT_720498](s) for exclusio n.
The available concentration data and PK parameter data for any  subjects excluded fro m the 
PK analysis set will be listed o nly. Concentration data for subjects excluded from the PK 
analysis set will be presented in the individual figures of concentration versus time plots.
11.1.3. Randomized Set
The Rando mized Set will consist of all subjects rando mized into the study .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038051] anned.
If circumstances should arise during the study  rendering the analysis inappropriate, or if in the 
meantime improved methods of analysis should come to light, different analyses may be 
perform ed. A SAP will not be written for the study. Any deviat ions from the statistical 
methodol ogy defined in this CSP, reasons for such deviat ions and all alternative/add itional 
statist ical analyses that m ay be perform ed will be described in the CSR. Such changes to 
analyses may be written into an abbreviated SAP, if appropriate. The verification and review 
of all stati stical modelingassumpt ions will be documented appropr iately.
All ori ginal  and derived parameters as well as demographic and disposit ion data will be listed 
and described using summary  stati stics. All safet y data (scheduled and unscheduled) will be 
presented in the data list ings.
Dem ographic and baseline data will be summarized for all randomized subjects. 
Pharmacokinet ic data will be summarized by [CONTACT_3148]. Safet y and tol erabilit y data will be 
summarized by  [INVESTIGATOR_24258], if applicable.
Frequency counts (n and percentages) will be made for each qualit ative varia ble. Descript ive 
statist ics (n, mean, SD, median, minimum and maximum) will be calculated for each 
quant itative variable (unless otherwise stated). Descript ive statist ics will only be presented if 
n≥ 3.
The fo llowing rul es will  apply to any  repeated safet y assessments occurring within each 
treatm ent peri od:
If the repeated measurement of a specific parameter occurs prior to IMP administration 
(Day  1), then the l ast obtained value prior to dosing will be used in the descript ive 
statist ics and in the calcula tion of  changes fro m baseline .
If the repeated measurement of a specific parameter occurs after IMP administration 
(Day 1), then the first (non -missing) value after dosing will be used in descriptive 
statist ics and in the calculat ion of changes fro m baseline.
The pl anned sequence for measurement of mult iple assessments at the same time point is 
described in Section 3.1.1 .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038052] visit, the fo llowing rul es will apply  
for any  repeated assessments:
If the repeated assessment occurs at screening the last available value will be used in the 
summary statist ics.
If the repeated a ssessment occurs at the Day [ADDRESS_1038053] ings will be performed using 
SAS® versio n 9.4or later.
11.2.2. Missing Data
Missing dates and times in the AE data will be handled as described in Sect ion10.1.[ADDRESS_1038054] ing will be presented and include the fo llowing: each subject’s 
rando mizat ion number, the subject’s full enrol lment number, the treatment to which the 
subject has been rando mized and the c ountry  where the Clinical Unit is located.
Subjects and/or data excluded fro m the PK analysis set will be listed including the reason for 
exclusio n. Subject disposit ion will  be summarized and will include the following informat ion: 
number of subjects rando mized and dosed, number and percentage of subjects complet ing the 
study  and the number and percentage of subjects who were withdrawn (including reasons for 
withdrawal). Di sposi tion data will be presented based on all subjects randomized.
Subject discont inuations will be listed including the date of study  exit, durati on of  treatm ent 
and reason for discont inuat ion. A list ing of informed consent response will also be presented.
[IP_ADDRESS]. Demographic and Baseline Data
Dem ographic vari ables (age, gender, race, ethnicit y, height, weight ,and BMI) will be listed 
by [CONTACT_1130]. Demographic characterist ics (age, gender, race, and ethnicit y) and subject 
characterist ics (height, weight ,and BMI) will be summarized separately for all randomized 
subjects. The denominator for percenta ges will be the number of rando mized subjects.
Medical history  data will be listed by [CONTACT_724306], descript ion of the 
disease/procedure, MedDRA SOC, MedDRA preferred term, start date and stop date (or 
ongoing if applicable).
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 73of 97A summary  of the nu mber and percentage of subjects who had relevant medical histories will 
be presented by  [CONTACT_758254].
11.2.4. Prior and Concomitant Medication and Drug Administration
[IP_ADDRESS]. Prior and Concomitant Medicatio n
Prior medicat ions are those that started and stopped prior to the first dose of IMP; all 
medicat ions taken after first dosing are considered as concomitant (including medicat ions that 
started prior to dosing and continued after). Prior medicat ion started within [ADDRESS_1038055] dose of IMP will be recorded also in the concomitant medicat ion module of 
ClinBase™.
Prior and concomitant m edicat ion will be listed by [CONTACT_758255]: reported name, preferred term, t he route of administration, dose, frequency, start 
date/time, duration ,and indicat ion. Pri or and concomitant medication will be coded according 
to the sponsor’s drug dictionary.
[IP_ADDRESS]. Study Intervention Administration
Study  intervent ion dates and times will be listed for each subject and treatment period.
11.2.5. Safety and Tolerability
All safet y data (scheduled and unscheduled) will be presented in the data list ings continuous 
variables will be summarized using descript ive statist ics (n, m ean, SD, min imum , median, 
maximum ) by [CONTACT_3227]. Categori cal variables will be summarized in frequency tables 
(frequency and proportion) by [CONTACT_3148]/dose group. The analysis of the safet y variables will 
be based on the safety  analysis set.
Adverse event s will be summarized by [CONTACT_758256]. 
Furtherm ore, list ings of SAEsand DAEs will be made. Adverse events that occur before 
dosing will be reported separately.
Tabulat ions and list ings of data for vital signs, clinical lab oratory  tests, ECGs, will be 
presented. Any  new or aggravated clinically  relevant abnorm al medical  physical  examinat ion 
finding co mpared to the baseline assessment will be reported as an AE. Data will be 
summarized for the observed values at each scheduled assessment, together with the 
corresponding changes (and/or percentage change) fro m the baseline when baseline is defined. 
Clinical laboratory  data will be reported in the unit s provided by [CONTACT_758257] m eeting, and in Système Inter national units in the CSR .
Out-of-range values for safet y laboratory  will be flagged in individual list ings as well as 
summarized descript ively using agreed reference ranges (eg, laboratory  ranges).
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038056] ion times, as well as derived sampling t ime deviat ions 
will be provided. Plasma concentrations and PK parameters will be summarized by [CONTACT_758258] (budesonide, glycopy rroni um,and form oterol) using appropri ate descri ptive 
statist ics. Where possible, the fo llowing descriptive statist ics will be presented: n, geometric 
mean, geometric CV, arithmet ic mean, arithmet ic SD, m edian, minimum ,and m aximum . For 
tmax, only  n, median, minimum ,and maximum will be presented.
The geometric mean is calcula ted as the exponent ial of the arithmet ic mean calculated using 
log-transform ed data.
The CV% i s calculated as where sis the SD of the log- transformed data.
Concentration data will be presented to the same number of significant figures as the data 
receiv ed from the bi oanaly tical laboratory; for PK parameters, the list ings will be presented 
according to the fo llowing rul es:
Cmax –will be presented to the same number of significant figures as received fro m the 
bioanalyt ical laboratory
tmax, λzlower and λzupper time limit –will be presented as received in the data, usually  
to 2 decimal places
AUC inf, AUClast, t ½λz, λz, CL/F, MRT inf, Vz/F, AUCextr, R sq adj will be presented to 
3significant figures
λzN –will be presented as an integer (no decimals)
For PK concentration data all descript ive statistics will be presented to [ADDRESS_1038057] ics will be presented according to the fo llowing 
rules:
Cmax, AUC inf, AUClast, t ½λz,λz, CL/F, MRT inf, Vz/F – all descript ive statist ics will 
be presented to 4 significant figures with the exception of the minimum and maximum 
which will be presented to 3 significant figures
tmax, λz l ower and λz upper –all descript ive statistics will be presented as received in the 
data, usually  to 2 decimal places
λzN, N –present as an integer  1 exp 1002  s
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 75of 97Plasma concentrations that are NQ or if there are missing values ( eg, no resul t [NR]) will be 
handled as fo llows:
Where there is NR, these will be set to missing.
At a time point where less than or equal to 50% of the values are NQ, all NQ values will 
be set to the LLOQ, and all descript ive statistics will be calculated.
At a time point where more than half o f the values are NQ, the mean, SD, geometric 
mean and CV% will be set to NC. The maximum value will be reported from the 
individual data, and the minimum and median will be set to NQ.
If all values are NQ at a time point, no descript ive statist ics will be calculated for that 
time point. N ot cal culated will be written in the field for SD and CV% and NQ will be 
written in fields for mean, geometric mean, minimum, median, and maximum.
The number of NQ values (n below LLOQ) will be reported f or each time po int.
Three observations > LLOQ are required as a minimum for a plasma concentration to be 
summarized. Two observat ions are presented as a minimum and maximum wit h the other 
summary statist ics as NC.
Data from subjects excluded from the PK a nalysis set will be included in the data list ings, but 
not in the descriptive statist ics or in the inferential statist ics.
Plasma concentrations for each analy te (budesonide, glycopy rroni um,and form oterol ) will  be 
listed by  [CONTACT_758259], subject and time point. Plasma concentrations will also be 
summarized by  [CONTACT_758224] t imes and 
appropriate descript ive statistics.
The stati stical analysis will be performed for the PK analysis set. Pharmacokinetic param eters 
will be calculated using non- compartmental analysis.
For each analyte, individual plasma concentrations versus actual time will be plotted in linear 
and semi -logarithmic scale wi th all treatm ent occasi ons overl aid on the sam e plot and separate 
plots for each subject. Combined individual plasma concentration versus actual times will be 
plotted in linear and semi -logarithmic scale for each treatment occasion and analy te. 
Geom etric mean pl asma concentrati on (± gSD) versus no minal sampling time will be plotted 
in linear and semi -logarithmic (no SD presented) scale wit h all treatment occasions overlaid 
on the same figure.
For m ean pl ots, below the limit of quant ificat ionvalues will  be handled as described for the 
summary tabulations; for individual p lots plasma concentrations which are NQ prior to the 
first quantifiable concentration will be set to a value of zero (linear plots only). After the first 
quant ifiable concentration, any NQ plasma concentrations will be regarded as missing. All 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038058] treatment BGF MDI HFO and reference 
treatm ent BGF MDI HFA based on the PK analysis set.
[LOCATION_003]Approach:
To establish the bioequivalence of the test treatment BGF MDI HFO and reference treatment 
BGF MDI HFA, the GMR and 90% CIs will be analy zed for PK param eters Cm ax, AUClast, 
and AUCinf o f analy tes budesonide, glycopy rronium ,and form oterol.
The TOST will be performed via a linear mixed effects model, with log -transformed PK 
param eter as dependent variable; sequence and period as fixed effects; subject and treatment 
nested within -subject as rando m effects. The e stimated GMR with 90% CIs will be provided.
For any  of Cmax, AUClast, or AUCinf, if the swr of the reference treatment is < 0.294 (ie, 
within-subject CV is < 30%), then the ABE method will be used. The acceptance criteria for 
90% CIs of GMR are the fixed l imits 80% to 125%.
For any  of Cmax, AUClast, or AUCinf, if swr is ≥ 0.[ADDRESS_1038059] 
variabilit y, then the RSABE method will be used. The acceptance limit s for 90% CIs of GMR 
are expanded to [U, L] = e ± k·swr, where k = 0.893.
Geom etricmean ratio must lie within 80% and 125%, regardless of the expanded acceptance 
limits for 90% CIs.
The acceptance criteria for GMR and the acceptance criteria for 90% CIs of GMR must be 
satisfied for each PK parameter and each analy te to concl ude the bioe quivalence.
Proposed SAS Code for PK Bioequivalence Analysis with Replicate Designs:
The FDA guidance for Industry  docum ent “Statistical approaches to establish bioequivalence” 
specifies the bioequivalence analysis of replicated design using a linear mixed effects m odel, 
with log-transformed PK parameter as dependent variable; sequence and period as fixed 
effects; subject and treatment (nested within -subject) as random effects 
(FDA Guidance 2001 ).
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 77 of 97 
 
EU Approach:
To establish the bioequivalence of the test treatment BGF MDI HFO and reference treatment 
BGF MDI HFA, the GMR and 90% CIs will be  analyzed for PK parameters Cmax, and 
AUClast of analytes budesonide, glycopyrronium, and formoterol.
The TOST will be performed via an analysis of variance model, with log-transformed PK 
parameter as dependent variable; sequence, period, treatment, and subject within sequence as fixed effects. The estimated GMR with 90% CIs will be provided.
For Cmax, if the swr of the reference treatment  the 
ABE method will be used. The acceptance criteria for 90% CIs of GMR are the fixed limits 
 
 
The ABE method will be applied for AUClast. The acceptance criteria for 90% CIs of GMR 
are the fixed limits 
Geometric mean ratio must lie within  regardless of the expanded acceptance 
limits for 90% CIs.
The acceptance criteria for GMR and the acceptance criteria for 90% CIs of GMR must be 
satisfied for each PK parameter and each analyte to conclude the bioequivalence.CCICCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 78 of 97Proposed SAS Code for PK Bioequivalence Analysis with Replicate Designs:
The EU approach compatible with Committee for Medicinal Products for Human Use
guideline specifies the bioequivalence analysis of replicated design using an analysis of 
variance model, with log-transformed PK parameter as dependent variable; sequence, period, treatment and subject within sequence as fixed effects (Annex I EMA, EMA Guideline 2010) .
 
 
11.3. Protocol Deviations
Protocol deviations are considered any dev iation from the CSP relat ing to a subject, and 
include the following:
!Inclusion/exclusion criteria deviations
!Dosing deviations (eg, incorrect treatment receiv ed, subject was not fasted as per the CSP
requirements prior to and after dosing)
!Time window deviations for safety and/or PK assessments
!Subjects receiving prohibited concomitant medications
!Other procedural and study conduct deviations recorded by [CONTACT_718169] a CSP
deviation log
The criteria for the assessment and reporting of CSP deviations will be stipulated in a separate 
study specific CSP deviation specification document. This will include a WAD which stipulates tolerance windows for safety and PK assessments. Measurements performed within 
these tolerance windows will not be considered as CSP deviations and will not be reported.
All CSP deviations will be discussed at the data review meeting prior to database hard lock in 
order to define the analysis sets for the study.
Important CSP deviations will be listed by [CONTACT_1130].Protocol deviations will be handled in accordance with Parexel SOPs.CCICCI
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 [ADDRESS_1038060] identifiers generated for the study will account for the number of 
randomized subjects per the sample size calculation (N = 108). For this study, a total of [ADDRESS_1038061] identifiers will be randomly assigned to 1 of 3 possible treatment sequences: ABB, BAB, BBA.CCI
CCI
Clinical Study Protocol [COMPANY_008]
BGF MDI – D5 985C00004 [ADDRESS_1038062] the Sponsor’s 
Lead Physician. If the PI [INVESTIGATOR_393877], the site’s staff will contact [CONTACT_978]’s deputy or may contact [CONTACT_2728]’s Lead Physician.
Name [CONTACT_720510] [CONTACT_758260]
[INVESTIGATOR_36113]: 
Email: 
Sponsor’s Lead Physician [COMPANY_008] AB
Tel: 
Email: 
12.2. Pregnancy
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008] except if the 
pregnancy is discovered before the study subject has received any study intervention.
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy.
Abnormal pregnancy outcomes (eg, spontaneous  abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.
Please refer to Section  [IP_ADDRESS] and Section  [IP_ADDRESS] for further details.
12.2.1. Maternal Exposure
If a subject becomes pregnant during the c ourse of the study, B GF MDI should be 
discontinued immediately.
Pregnancy itself is not regarded as an AE unless there is a suspi[INVESTIGATOR_301668] a contraceptive medication. Congenital [COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003]
[COMPANY_003]
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 81of 97anomalies/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions wit hout complicat ions should not be handled as AEs. The outcome 
of all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy, normal 
birth ,or congenital anomaly ) shoul d be f ollowed up and documen ted even if the subjec t was 
discontinued fro m the study .
If any pregnancy  occurs in the course of the study , then the investigator or other site personnel 
informs the appropriate [COMPANY_008] representatives within 1 day (ie, immediately but no 
later than 2 4 hours ) of when he or she beco mes aware of i t.
The designated [COMPANY_008] representative works with the invest igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site wi thin 1 or 
5calendar days for SAEs (see CSP process for SAE reporting) and within 30 days for all other 
pregnancies.
The same timelines apply when outcome informat ion is available.
Please refer to Section [IP_ADDRESS] for further details.
12.2.2. Paternal Exposure
There i s no restri ction on fathering children or donating sperm during the study .
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038063] access is allowed only for authorized people for monitoring and 
auditing purposes. Source document s will be handled, stored ,and archived according to in 
house procedures.
The Investigator's Site File will be archived by [CONTACT_718196] 15years after complet ion of the 
study .
13.2. Publication of Study Results
All o f the study  informat ion and data collected duri ng the study  are confident ial and the 
property  of [COMPANY_008]. After completion o f the study , [COMPANY_008] may prepare a jo int 
publicat ion with the invest igator . The invest igator must undertake not to submit any data from 
this CSP for publicat ion without prio r consent of [COMPANY_008] at a mutually agreed time.
Authorship will be determined by  [CONTACT_73008] h Internat ional Committee 
of Medical Journal Editors authorship requirements.
13.3. Clinical Study Report
An integrated CSR will be prepared in accordance with the standards of the ICH guideline for 
structure and content of CSRs (ICH E3). Copi[INVESTIGATOR_758217] h regulatory  requi reme nts and Parexel
SOPs. In the event of premature termination o f the study  or other condi tions specified in 
ICH E3, an abbreviated CSR may be prepared.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038064]
Annex IEMA
Annex I EMA/582648/2016. Available at: 
https://www.ema.europa.eu/en/documents/other/31 -annex -i-statistical-analysis -methods -
compatible-ema-bioequivalence -guideline_en.pdf. Accessed 17 May  2022.
EMA Guideline 2010
EMA Guideline on the Investigation of Bioequivalence 2010. Available at: 
https://w ww.ema.europa.eu/en/documents/scient ific-guideline/guideline -invest igation-
bioequivalence -rev1_en.pdf. Accessed 17 May  2022.
FDA Guidance 2001
FDA Guidance for Industry  docum ent “Stati stical approaches to establishing bioequivalence” 
(2001). Available at: https://www.fda.gov/media/[ZIP_CODE]/download. Accessed [ADDRESS_1038065] 15;200(8):e70 -e88.
Investigator’s Brochure 2022
Budesonide, Glyco pyrroni um and Form oterol Fumarate Inhalat ion Aerosol (BGF MDI); 
Budesonide and Formoterol Fumarate Inhalat ion Aerosol (BFF MDI); Budesonide Inhalat ion 
Aerosol (BD MDI); Glycopy rroni um Inhalat ion Aerosol (GP MDI) (Also known as PT010 
[BGF MDI], PT009 [BFF M DI], PT008 (BD MDI); PT001 (GP MDI); Edition Number 8.0, 
[ADDRESS_1038066], Hankinson JL, 
Ip MS, Zheng J, Stocks J; ERS Global Lung Functio n Init iative. Mult i-ethnic reference values 
for spi[INVESTIGATOR_14436] 3 -95-yr age range: the global lung function 2012 equations. Eur Respir 
J. 2012 Dec;40(6):1324-43.
Tothfalusi and Endrenyi 2011
Tothfalusi L, Endrenyi L. Sample sizes for designing bio equivalence studies for highly 
variable drugs. J Pharm Sci. 2012;15(1):73-84.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 84of 9715. APPENDICES
Appendix AAdditional Safety Information
Further Guidance on the Definition of a Serious Adverse Event
Life-threatening
“Life -threatening” means that the subject was at immediate risk of death from the adverse
event (AE) as it occurred, or it is suspected that use or continued use of the product would 
resul t in the subject’s death. “Life -threatening” does not m ean that had an AE occurred in a 
more severe form  it might have caused death (eg, hepat itis that resol ved without hepat ic 
failure).
Hospi[INVESTIGATOR_96698] a serious adverse event (SAE), 
although the reasons for it may  be (eg, bronchospasm, laryngeal edema). Hospi[INVESTIGATOR_720462]/or surgical operations p lanned before or during a study  are not considered AEs if the 
illness or disease existed before the subject was enrolled in the study , provi ded that i t did not 
deteri orate in an unexpected way  during the study .
Important Medical Event or Medical Interventi on
Medical and scientific judgment should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi [INVESTIGATOR_3094], disabilit y or incapaci ty but may jeopardi ze the subject or may require 
medical intervention to prevent one or more outcomes listed in the definit ion of serious. These 
shoul d usually be considered as serious.
Simply stoppi[INVESTIGATOR_758218]; 
medical judgment must be used.
Angioedema not severe enough to require intubation but requiring intravenous
hydrocortisone treatment
Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anemia requiring blood transfusio n, etc .) or 
convulsio ns that do not result in hospi[INVESTIGATOR_3094]
Development of drug dependency or drug abuse
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 85of 97A Guide to Interpre ting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
is a “reasonable possibilit y” that an AE may have been caused by [CONTACT_33641].
Time Course. Exposure to suspect drug. Has the subject actua lly received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and to xicology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?
No al ternative cause. The AE cannot be reasonably explained by [CONTACT_758261], other drugs, other host, or environmental factors.
Re-challenge experience. Did the AE reoccur if the suspected drug was reintroduced after 
having been stopped? AstraZen eca woul d not normally  recommend or support a 
re-challenge.
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship?
In difficult cases, other factors could be considered such as:
Is this a recognized feature of overdose of the drug?
Is there a known mechanism?
Causalit y of “related” is m ade if fo llowing a review of the relevant data, there is evidence for 
a “reasonable possibilit y” of a causal relat ionship for the individual  case. The expressio n 
“reasonable pos sibilit y” of a causal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an info rmed judgment. Wi th no available facts or arguments to suggest a 
causal relat ionship, the event(s) will be assessed as “not related”.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038067] Samples
International Airline Transportation Associat ion (IATA) classifies bio hazardous agents into 
3categori es (http://www.i ata.org/whatwedo/cargo/dangerous_goods/infectious
_substances.ht m). For transport purposes, the classificat ion of infect ious substances according 
to risk groups was removed from the Dangerous Goods Regulations (DGR) in the 46th edit ion 
(2005). Infect ious substances are now classified either as Category  A, Category B or Exem pt. 
There i s no di rect relati onship between Risk Groups and Categories A and B.
Category AInfectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal  disease in 
otherwi se healt hy humans or animals. Category A pathogens are for example, Ebola and Lassa 
Fever viruses :
Are to be packed and shipped in accordance wit h IATA Instruction 602.
Category B Infectious Substances are infect ious substances that do not meet the criteria for 
inclusio n in Category  A. Category B pathogens are for example, hepat itis A, B, C, D ,and E
viruses, and human immunodeficiency  virus (HIV) ty pes 1 and 2. They  are assi gned the 
following UN number and proper shippi[INVESTIGATOR_72919]:
UN3373 – Biological Substance, Category B
Are to be packed in accordance with UN 3373 and IATA 650.
Exempt refers to all o ther materials wit h minimal ri sk of containing pathogens.
Clinical trial samples will fall into Category B or Exempt under IATA regulations.
Clinical trial samples will routinely be packed and transported at ambient temperature in 
IATA 650 com pliant packag ing.
(http://www.iata.org/whatwedo/cargo/dangerous_goods/infect ious_substances.ht m)
Biological samples transported in dry ice require additional dangerous goods 
specification for the dry ice content.
An IATA co mpliant courier and packaging materials should be used for packing and 
transportation. Packing should be done by [CONTACT_73013], as applicable.
Samples routinely transported by  [CONTACT_73014] a safe and appropri ate way  to contain 
any risk of infect ion or contaminat ion by [CONTACT_73015]/containment materials at all times. The IATA [ADDRESS_1038068] or rail transpor t is 
used.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 87of 97Appendix CActions Required in Cases of Combined Increase of 
Aminotransferase and Total Bilirubin -Hy’s Law
Introduction
This Appendix describes the process to be fo llowed in order to ident ify and appropriately 
report Potential Hy’s Law (PHL) cases and Hy ’s Law (HL) cases. It is not intended to be a 
comprehensive gui de to the m anagement of el evated liver biochemistries.
During the course of the study  the invest igator will remain vigilant for increases in liver 
biochemistry . The invest igator is responsible for determining whether a subject meets 
potenti al PHL cri teria at any  point duri ng the study.
All sources of l aboratory  data are appropri ate for the determinat ion of PHL and HL events; 
this includes samples taken at scheduled study  visits a nd other visits including central and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple, PHL 
criteria coul d be m et by  [CONTACT_720506] (ALT) from a central laboratory  
and/or elevated total bilir ubin (TBL) from  a local laboratory .
The invest igator will also review adverse event (AE) data (for example, for AEs that may 
indicate elevat ions in liver biochemistry ) for possible PHL events.
The invest igator participates, together with [COMPANY_008] clinic al project representatives, in 
review and assessment of cases meet ing PHL criteria to agree whether HL criteria are met. HL 
criteria are met if there is no alternat ive explanation for the elevat ions in liver biochemistry  
other than Drug -Induced Liver Injur y (DILI) caused by  [CONTACT_720507] 
(IMP).
The invest igator is responsible for recording data pertaining to PHL/HL cases and for 
reporting serious adverse events (SAEs) and AEs according to the outcome o f the review and 
assessment in l ine with standard safet y reporting processes.
Definitions
Potential Hy’s Law
Aspartate aminotransferase (AST) or ALT ≥ 3 x upper limit of normal (ULN) together with
TBL ≥ [ADDRESS_1038069] at any  point during the study  following the start of study  medicat ion 
irrespe ctive of an increase in alkaline phosphatase (ALP).
Hy’s Law (HL)
Aspartate aminotransferase or ALT ≥ [ADDRESS_1038070] together with TBL ≥ [ADDRESS_1038071], where no 
other reason, other than the IMP, can be found to explain the combinat ion of increases, eg, 
elevated ALP indicat ing cholestasis, viral hepat itis, another drug.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038072] precede or be coincident with (ie, on the 
same day ) the el evati on in TBL, but there is no specified timeframe within which the 
elevations in transamin ases and TBL must occur.
Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL i t is important to perform a comprehensive review of 
laboratory  data for any  subject who m eets any of the fo llowing i dentificat ion criteria in 
isolation or in combinat ion:
Aspartate aminotransferase ≥ [ADDRESS_1038073]
Alanine aminotransferase ≥ [ADDRESS_1038074]
Total  bilirubin ≥ [ADDRESS_1038075] igator will wit hout delay  review each new laboratory  report and if the ident ificat ion 
criteria are met will:
Notify  the AstraZene ca representative .
Determine whether the subject meets PHL criteria (see Section 2 within this appendix for 
definit ion) by  [CONTACT_42574] l aboratory  reports from  all previ ous visi ts.
Prom ptly enter the laboratory  data into the l aboratory  CRF m odule(s).
Follow -up
Potential Hy’s Law Criteria Not Met
If the subject does not meet PHL criteria the investigator will:
Inform  the [COMPANY_008] representative that the subject has not met PHL criteria .
Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided in 
the clinical study  protocol  (CSP) .
Potential Hy’s Law Criteria Met
If the subject does meet PHL criteria the invest igator will:
Notify  the [COMPANY_008] representative who will then inform the central Study  Team .
Within [ADDRESS_1038076] igator will report the case as an SAE of 
PHL; serious criteria “Important Medical Event” and causalit y assessment “yes/related” 
according to CSP process for SAE reporting .
For subjects that met PHL criteria prior to starting IMP, the invest igator is not required to 
submit a PHL SAE unless there is a significant change1in the subject’s condit ion.
1A “significant ”change in the subject’s condition refers to a clinically relevant change in any of the individual 
liver biochemistry parameters (ALT, AST or TBL) in isolation or in combination, or a clinically relevant change 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 89of 97The Study  Physician contacts the investigator , to provide guidance, discuss and agree an 
approach for the study  subjects’ foll ow-up (including any further laboratory  testing) and 
the continuous review o f data.
Subsequent to this contact [CONTACT_33157]:
oMoni tor the subject until liver biochemistry  parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes fo llow-up SAE Form as required.
oInvest igate the etiology of  the event and perform diagnostic investigat ions as 
discussed wi th the Study  Physician. This includes deciding which the tests 
available in the HL laboratory  kit shoul d be used (if applicable).
oCom plete the 3 liver CRF modules as informat ion beco mes available.
Review and Assessment of Potential Hy’s Law Cases
The instructions in this sect ion shoul d be fo llowed for all  cases where PHL cri teria are met.
As soon as possible after the biochemistry  abnormalit y was ini tially detected, the Study  
Physician contacts the invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL criteria other th an DILI caused by  [CONTACT_86184], to ensure timely analysis and reporting to healt h authorit ies wit hin [ADDRESS_1038077] or ALT and TBL elevations, 
a determination of whether the alternat ive explanatio n is an AE will be made and 
subsequent ly whether the AE meets any criteria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanatio n on the 
appropriate CRF module(s)
If the alternat ive explanat ion is an AE/SAE: update the previously submitted PHL SAE 
and AE CRF entries accordingly  with the new info rmation (reassessing event term; 
causalit y and seri ousness cri teria) fo llowing the Astra Zeneca standard processes
in associated symptoms . The determination of whether there has been a significant change will be at the 
discretio n of the investigator , this may be in consultation with the Study Physici an if there is any  uncertainty.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038078] or ALT and TBL 
elevations other than the IMP:
Send updated SAE (report term “Hy’s Law”) according to [COMPANY_008] standard 
processes
The “Medically Important” seriousness criterion should be used if no other 
seriousness cri teria apply
As there is no alternat ive explanation for the HL case, a causalit y assessment of 
“related” should be assigned
If there is an unavo idable delay o f over 15 calendar days in obtain ing the informat ion 
necessary  to assess whether the case meets the criteria for HL, then it is assumed that there is 
no al ternative explanat ion until such t ime as an informed decisio n can be made:
Provi de any further update to the previously  submitted SAE of PHL (report term  now 
“Hy’s Law case”), ensuring causalit y assessment is “related to IMP” and seriousness 
criterion is “medically  important”, according to CSP process for SAE reporting .
Continue fo llow-up and review according to agreed plan. Once the nec essary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review an d 
amending the reported term if an alternat ive explanat ion for the liver biochemistry  
elevations is determined.
Laboratory Tests
The list below represents the standard, comprehensive list of fo llow-up tests which are 
recommended but not mandatory  when using a central laboratory . For studi es using a l ocal 
laboratory , the list m ay be modified based on clinical  judgment. Any  test resul ts need to be 
recorded.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 91of 97Hy’s Law laboratory kit for central laboratories (18 December 2018)
Additional standard biochemistr y and 
coagulatio n testsGGT (gamma glutamyl transpeptidase (transferase))
LDH (lactate dehydrogenase)
Prothrombin time
INR (international normalized ratio)
Viral hepatitis IgM anti -HAV IgG anti -HCV
IgM and IgG anti -HBc HCV RNA1
HBsAg IgM anti -HEV
HBV deoxy ribonucleic acid HEV RNA
Other viral infections IgM & IgG anti -CMV
IgM & IgG anti -HSV
IgM & IgG anti -EBV
Alcoholic hepatitis Carbohydrate deficient transferrin (CD -transferrin)
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal Ab (Anti -LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases alpha -1-antitry psin
Ceruloplasmin
Iron
Ferritin
Transferrin
Transferrin saturation
1HCV RNA is only tested when anti -HCV is positive or inconclusive.
REFERENCES
Aithal GP, Watkins PB, Andrade RJ, et al. Case definit ion and phenoty pe standardizat ion in 
drug‐induced liver injury. Clinical Pharmaco logy & Therapeut ics 2011;89(6):806–15.
FDA Guidance for Industry  (issued July  2009) “Drug -induced liver injury: Premarket ing 
clinical evaluat ion”.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 92of 97Appendix DMedical Device AEs, ADEs, SAEs, SAD Es, [LOCATION_003]DEs and 
Medical Device Deficiencies: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting in Medical 
Device Studies
The definit ions and procedures detailed in this appendix are in accordance wit h 
International Organizat ion for Standardizat ion [ZIP_CODE] and European Medical Device 
Regulation (MDR) 2017/745 for clinical device research (if applicable), in particular 
Medical Device Coordinat ion Group (MDCG) 2020 -10/1 Safet y reporti ng in clinical 
investigat ions of m edical  devices.
Both the invest igator and the sponsor will comply with all local reporting requirements 
for medical devices.
The detecti on and docum entati on procedures described in this protocol apply  to all  
sponsor m edical devices provided for use in the study . See Secti on5.4 for details o f 
sponsor m edical devices.
Definition of Medical Device AE and ADE
Medical Device AE and ADE Definition
An adverse event (AE) is any untoward medical occurrence in a clinical study  subject, 
users, or other persons, temporally associated with the use of study  intervent ion, whether 
or not considered related to the investigat ional medi cal device. An AE can therefore be 
any unfavorable and unintended sign (including an abnormal laboratory  finding), 
symptom , or disease (new or exacerbated) te mporally associated with the use of an 
investigat ional medical device. This definit ion includes events related to the 
investigat ional medical device or comparator and events related to the procedures 
involved.
An adverse device effect (ADE) is defined as a n AE rel ated to the use of an 
investigat ional medical device. This definit ion includes any AE result ing from 
insufficient or inadequate instructions for use, deployment, implantation, installat ion, or 
operati on, or any  malfunct ion of the invest igational medical  device as well as any event 
resul ting fro m use error or from intentional misuse of the invest igational medical device.
Definition of Medical Device SAE, SADE and [LOCATION_003]DE
A Medical Device Serious Adverse Event (SAE) is an /any SAE that:
Led to death.
Led to seri ous deteri oration in the healt h of the subject, that either resulted in:
A life-threatening illness or injury. The term “life -threatening” in the definit ion of 
“serious” refers to an event in which the subject was at risk of death at the time of t he 
event. It does not refer to an event, which hypothetically might have caused death if it 
were m ore severe.
A permanent impairment of a body  structure or a body  function.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 93of 97Inpat ient or prolonged hospi[INVESTIGATOR_3094]. Planned hospi [INVESTIGATOR_95658] a pre -exist ing 
condi tion, or a procedure required by [CONTACT_760], without serious deterioration in 
healt h, is not consi dered an SAE.
Medical or surgical intervent ion to prevent life -threatening illness or injury  or 
perm anent impairment to a b ody structure or a body  function.
Chronic disease (MDR 2017/745).
Led to fetaldistress, fetaldeath, or a congenital anomaly or birth defect.
SADE Definition
A serious adverse device effect (SADE) is defined as an ADE that has resulted in any o f 
the consequences characterist ic of a n SAE.
Any medical device deficiency that might have led to an SAE if appropriate action had 
not been taken, intervent ion had not occurred, or circumstances had been less fortunate.
[LOCATION_003]DE Definition
An unant icipated SADE ([LOCATION_003]DE) (also identified as UADE i n [LOCATION_002] Regulat ions 
21CFR 813.3), i s defined as a SADE that by  [CONTACT_5942], incidence, severit y, or outcom e 
has not been ident ified in the current risk analysis (see Section 3.4 for risk -benefit 
assessment of the device).
Definition of M edical Device Deficiency
Medical Device Deficiency Definition
A medical device deficiency is an inadequacy of a medical device wit h respect to its 
ident ity, qualit y, durabilit y, reliabilit y, safet y, or perform ance. Medi cal device 
deficiencies include malfunctions, use errors, and informat ion supplied by  [CONTACT_13989].
Recording and Follow -up of AE and/or SAE and Medical Device Deficiencies
AE, SAE, and Medical Device Deficiency Recording
When an AE/SAE/medical device deficiency occurs, it is the responsibilit y of the 
investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, 
and diagnostics reports) related to the event.
The invest igator will then record all relevant AE/SAE/medical device deficiency 
inform ation in the subject’s me dical  records, in accordance with the invest igator’s normal 
clinical practice and on the appropriate form.
It is notacceptable for the invest igator to send photocopi[INVESTIGATOR_9238]’s medical 
records to the Sponsor in lieu of co mpletion of the AE/SAE/med ical device deficiency  
form.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 94of 97There m ay be instances when copi[INVESTIGATOR_758219] . In this case, all subject identifiers, with the exception o f the subject number, 
will be redacted on the copi[INVESTIGATOR_205731] l records before submissio n to the sponsor.
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be docume nted as the AE/SAE.
For m edical device deficiencies, it is very  important that the invest igator describes any 
corrective or remedial act ions taken to prevent recurrence of the deficiency.
A remedial act ion is any action other than routine maintenance or se rvicing o f a 
medical device where such act ion is necessary  to prevent recurrence of a medical 
device deficiency. This includes any amendment to the medical device design to 
prevent recurrence.
Assessment of Intensity
The invest igator will make an assessme nt of intensit y for each AE/SAE/m edical device 
deficiency reported during the study  and assign it to one of the following categories:
Mild: An event that is easily tolerated by [CONTACT_423], causing minimal disco mfort and not 
interfering wi th everyday act ivities.
Moderate: An event that causes sufficient discomfort and interferes wit h norm al everyday 
activit ies.
Severe: An event that prevents normal every day activi ties. An AE that is assessed as 
severe should not be confused with an SAE. “Severe” is a catego ry used for rating the 
intensity of an event; both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least [ADDRESS_1038079] igator is obligated to assess the relationship between study intervent ion and each 
occurrence of each AE/SAE/medical device deficiency. A “reasonable possibilit y” of a 
relationship conveys that there are facts, evidence, and/or arguments to suggest a causal 
relationship, rather than a relat ionship, cannot be ruled out. The invest igator will use clinical 
judgment to determine the relationship. Alternative causes, such as underlying disease(s), 
concomitant therapy , and other ri sk factors, as well as the temporal relat ionship of the event to 
study  interventi on administrati on will be considered and investigated. The invest igator will 
also consult the Investigator’s Brochure and/or Product Information, for marketed products in 
his/her assessment.
For each AE/SAE/medical device deficiency , the investi gator must document in the medical 
notes that he/she has reviewed the AE/SAE/medical device deficiency and has provided an 
assessment of causalit y. There may  be situations in which an SAE h as occurred ,and the 
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 [ADDRESS_1038080] igator may change his/her opi[INVESTIGATOR_3078] n of causalit y in light of fo llow-up inform ation and 
send an SAE fo llow-up report wi th the updated causalit y assessment. The causalit y 
assessment is one of the cri teria used when determining regulatory  reporti ng requirements.
For the purpose of harmonizing reports, each SAE will be classified accor ding to 5different 
levels o f causalit y. The sponsor and the invest igators will use the fo llowing definit ions to 
assess the relat ionship of the SAE to the invest igatio nal2device or procedures.
Not related: Rel ationship to the device or procedures can be e xcluded when:
the event has no temporal relat ionship wit h the use of the invest igational device or the 
procedures.
the seri ous event does not follow a known response pattern to the medical device (if the 
response pattern is previously  known) and i s biologically implausible.
the discont inuat ion of medical device applicat ion or the reducti on of  the l evel of 
activat ion/exposure -when clinically feasible -and reintroduction of its use (or increase 
of the l evel of activation/exposure), do not impact on the seri ous event.
the event invo lves a body -site or an organ not expected to be affected by  [CONTACT_10398].
the seri ous event can be attributed to another cause (eg, an underlying or concurrent 
illness/clinical condit ion, an effect of another dev ice, drug, treatment, or other risk 
factors).
the event does not depend on a false result given by [CONTACT_5749], when applicable.
In order to establish the non -relatedness, not all the criteria listed above might be met at the 
same time, depending on the ty pe of device/procedures and the serious event.
Unlikely: The rel ationship wi th the use of the device seems not relevant and/or the event 
can be reasonably explained by [CONTACT_5748], but addit ional information may be 
obtained.
Possible: The rel ationship wit h the use of the investigat ional device is weak but cannot be 
ruled out com pletely . Alternative causes are al so possible (eg, an underlying or 
concurrent illness/ clinical condit ion or/and an effect of another device, dr ug,or 
treatm ent). Cases w here rel atedness cannot be assessed or no informat ion has been 
obtained should also be classified as possible.
2Investigational device: any device object of the clinical investigation, including the comparators
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 96of 97Probable : The rel ationship wit h the use of the investigat ional device seems relevant 
and/or the event cannot be reasonably  explained by  [CONTACT_5748], but addit ional 
inform ation may be obtained.
Causal relat ionship : the seri ous event is associated with the invest igational device or with 
procedures bey ond reasonable doubt when:
the event is a known side effect of the product category  the device belo ngs to or of 
similar devices and procedures.
the event has a temporal relat ionship wit h invest igational device use/applicat ion or 
procedures.
the event invo lves a body -site or organ that :
othe invest igational device or proce dures are applied to.
othe invest igational device or procedures have an effect on.
the seri ous event fo llows a known response pattern to the medical device (if the 
response pattern is previously  known).
the discont inuat ion of medical device applicat ion (or reduction of the level of 
activat ion/exposure) and reintroduction of its use (or increase of the level of 
activat ion/exposure), impact on the serious event (when clinically feasible).
other possible causes (eg ,an underlying or concurrent illness/ clinical condi tion 
or/and an effect of another device, drug or treatment) have been adequately ruled out.
harm to the subject is due to error in use.
the event depends on a false result given by [CONTACT_5749], when applicable.
In order to establish the relatedness, not all the criteria listed above might be met at the same 
time, depending on the ty pe of device/procedures and the serious event.
Follow -up of AE/SAE/Medical Device Deficiency
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by [CONTACT_325740]/or causalit y of the AE/SAE/medical device deficiency as fu lly as 
possible. This may include addit ional laboratory  tests or invest igations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a subject dies during participation in the study  or during a recognized fo llow-up peri od, 
the invest igator will provide the Sponsor with a copy  of any post -mortem findings 
including histopathology .
New or updated informat ion will be recorded in the originally co mpleted form.
The invest igator will submit any updated SAE data to the Sponsor within 24 hours of 
recei pt of the inform ation.
Clinical Study Protocol [COMPANY_008]
BGF MDI –D5985C00004 12 July 2022
CONFIDENTIAL AND PROPRIETARY 97of 97Reporting of SAEs
SAE Reporting to the Sponsor via Paper Data Collection Tool
Facsimile transmissio n of the SAE paper data collection tool is the preferred method to 
transmit this informat ion to the s tudy phys ician .
In rare circumstances and in the absence of facsimile equipment, notificat ion by [CONTACT_13186] a copy  of the SAE paper data collect ion tool  sent by  [CONTACT_208895] m ail or 
couri er service.
Initial notificati on via telephone does not replace the need for the invest igator to complete 
and sign the SAE paper data collection tool within the designated reporting time frames.
Contacts for SAE reporting can be found in the Safety  Handling Pl an.
Reporting of SADEs
SADE Reporting to the Sponsor
NOTE: There are addit ional reporting obligat ions for m edical device deficiencies that are 
potenti ally related to SAEs that m ust fulfillthe legal  responsibilit y to notify appropri ate 
regul atory  authori ties and other entit ies about certain safet y informat ion relating to m edical  
devices being used in clinical studies.
Any medical device deficiency that is associated wit h an SAE must be reported to the 
sponsor within 24 hours after the investigator determines that the event meets the 
definit ion of a medical device deficiency .
The sponsor will review all medical device deficiencies and determine and document in 
writing whether they  coul d have l ed to an SAE. These medical device deficiencies will be 
reported to the regulatory  authori ties and IRBs/IECs as required by n ational regulat ions.
Contacts for SAE reporting can be found in the Safety  Handling Pl an.
6,*1$785(3$*(
7KLVLVDUHSUHVHQWDWLRQRIDQHOHFWURQLFUHFRUGWKDWZDVVLJQH G
HOHFWURQLFDOO\DQGWKLVSDJHLVWKHPDQLIHVWDWLRQRIWKHHOHFWU RQLFVLJQDWXUH
'RFXPHQW1DPH GFFVSY
'RFXPHQW7LWOH '&&OLQLFDO6WXG\3URWRFROYHUVLRQ
'RFXPHQW,' 'RF,'
9HUVLRQ/DEHO &855(17/$7(67$[ZIP_CODE]('
6HUYHU'DWH
GG000\\\\++PPµ87&¶=6LJQHGE\ 0HDQLQJRI6LJQDWXUH
-XO87& 0DQDJHPHQW$SSURYDO
-XO87& &RQWHQW$SSURYDO
-XO87& &RQWHQW$SSURYDO
-XO87& &RQWHQW$SSURYDO
-XO87& &RQWHQW$SSURYDO
1RWHV'RFXPHQWGHWDLOVDVVWRUHGLQ$1*(/DQ$VWUD=HQHFD GRFXPHQWPDQDJHPHQWV\VWHP[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]